Exclusive Channel Collaboration Agreement



 Exhibit 10.1 

CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 

EXCLUSIVE CHANNEL COLLABORATION AGREEMENT 

THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the
“Agreement”) is made and entered into effective as of June 9, 2015 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with
offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876, U.S.A. (“Intrexon”), Intrexon Actobiotics NV, a naamloze vennootschap under Belgian law with registered offices at Technologiepark 4, 9052 Zwijnaarde (CBE no.
0882.251.820 (Ghent), Belgium (“Actobiotics”), and ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634, U.S.A.
(“Oragenics”). Intrexon and Actobiotics together on the one hand and Oragenics on the other hand may be referred to herein individually as a “Party”, and collectively as the “Parties.” 

RECITALS 

WHEREAS, Intrexon has expertise in and owns or controls proprietary technology relating to the
identification, design and production of genetically modified cells, DNA vectors and in vivo control of expression; 

WHEREAS, Actobiotics (formerly known as ActoGeniX NV and now legally operating under the name above), a
wholly-owned subsidiary of Intrexon, Controls proprietary technology known as AG013 and a related L. lactis expression platform; and 

WHEREAS, Oragenics now desires to become Intrexon’s exclusive channel collaborator with respect to
such technology for the purpose of developing the Program (as defined herein), and Intrexon is willing to appoint Oragenics as a channel collaborator in such field under the terms and conditions of this Agreement. 

NOW THEREFORE, in consideration of the foregoing and the covenants and promises contained
herein, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 

As used in this Agreement, the following capitalized terms shall have the following meanings: 

1.1 “Actobiotics IP” means all Information, Patents, and proprietary biological materials that (a) are Controlled
by Actobiotics as of the Effective Date or during the Term and (b) are reasonably required or useful for Oragenics to conduct the Program. For the avoidance of doubt, the Actobiotics IP shall include the AG013 Regulatory Rights, and any
Information, Patents, and proprietary biological materials relating to AG013 and to other L. lactis strains under development that express human Trefoil Factor. 








 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.2 “Affiliate” means, with respect to a particular Party, any other
person or entity that directly or indirectly controls, is controlled by, or is in common control with such Party. As used in this Section 1.2, the term “controls” (with correlative meanings for the terms “controlled by” and
“under common control with”) means the ownership, directly or indirectly, fifty percent (50%) or more of the voting securities or other ownership interest of an entity, or the possession, directly or indirectly, of the power to direct
the management or policies of an entity, whether through the ownership of voting securities, by contract, or otherwise. Notwithstanding the foregoing, Third Security shall be deemed not to be an Affiliate of Intrexon or Oragenics, and neither Party
shall be deemed to be an Affiliate of the other Party. In addition, any other person, corporation, partnership, or other entity that would be an Affiliate of a Intrexon or Oragenics solely because it and Intrexon are under common control by Randal
J. Kirk or by investment funds managed by Third Security or an affiliate of Third Security shall also be deemed not to be an Affiliate of Intrexon or Oragenics. Further notwithstanding the foregoing, none of the KFLP Group shall be deemed to be an
Affiliate of Oragenics, and any person, corporation, partnership, or other entity that would otherwise be an Affiliate of Oragenics solely because it and Oragenics are under common control by a member of the KFLP Group shall not be deemed to be an
Affiliate of Oragenics. 
 1.3 “AG013” shall mean the existing drug product candidate as described in
Investigational New Drug application number 13995 filed with the FDA and under clinical development as of the Effective Date comprising genetically modified L. lactis that expresses a human Trefoil Factor and that is indicated for the
treatment of oral mucositis, which regulatory application, corresponding drug product candidate and intellectual property rights are owned by Actobiotics and licensed to Oragenics in accord with the terms and conditions of this Agreement. 

1.4 “AG013 Regulatory Rights” means all Information Controlled by Actobiotics (or otherwise by Intrexon) and existing
as of the Effective Date relating to the regulatory approval of AG013, including regulatory filings, data, clinical trial reports, and rights thereunder. 

1.5 “Applicable Laws” has the meaning set forth in Section 8.2(d)(xii). 

1.6 “Approval Milestone Event” means the first to occur for a particular Oragenics Product of (i) the First
Commercial Sale of such Oragenics Product anywhere in the Territory, or (ii) the ninetieth (90th) day after the approval of an FDA New Product Application for such Oragenics Product by
the FDA or equivalent regulatory action in a foreign jurisdiction. 
 1.7 “Authorizations” has the meaning set forth
in Section 8.2(d)(xii). 
 1.8 “CC” has the meaning set forth in Section 2.2(b). 

1.9 “Channel-Related Program IP” has the meaning set forth in Section 6.1(c). 

  
 2 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.10 “Claims” has the meaning set forth in Section 9.1. 

1.11 “CMCC” has the meaning set forth in Section 2.2(b). 

1.12 “Committees” has the meaning set forth in Section 2.2(a). 

1.13 “Commercialize” or “Commercialization” means any activities directed to marketing, promoting,
distributing, importing for sale, offering to sell and/or selling Oragenics Products. 
 1.14 “Commercialization Milestone
Event” means any one of the Phase II Milestone Event, the Phase IIb/III Milestone Event, the Regulatory Approval Application Milestone Event, the Approval Milestone Event, the New Indication Milestone Event, and the New Product Milestone
Event. 
 1.15 “Commercial Sale” means for a given product and country the sale for value of that product by a Party
(or, as the case may be, by an Affiliate or permitted sublicensee of a Party), to a Third Party after regulatory approval (if necessary) has been obtained for such product in such country. 

1.16 “Company Sale” means the sale of Oragenics, whether in a single transaction or in a series of related
transactions that are consummated contemporaneously (or consummated pursuant to contemporaneous agreements), to one or more Third Parties on an arm’s length basis, pursuant to which such Third Party or Third Parties acquires (i) (whether
by merger, consolidation, sale or transfer of capital stock, recapitalization, or otherwise) more than fifty percent (50%) of Oragenics’ common stock other than a Reverse Merger, or (ii) all or substantially all of the assets of
Oragenics determined on a consolidated basis. 
 1.17 “Complementary In-Licensed Third Party IP” has the meaning set forth
in Section 3.8(a). 
 1.18 “Confidential Information” means each Party’s confidential Information,
inventions, non-public know-how or non-public data disclosed pursuant to this Agreement or any other confidentiality agreement between the Parties and shall include, without limitation, manufacturing, technical, marketing, financial, personnel and
other business information and plans, whether in oral, written, graphic or electronic form. 
 1.19 “Control” means,
with respect to Information, a Patent or other intellectual property right, that a Party owns or has a license from a Third Party to such right and has the ability to grant a license or sublicense as provided for in this Agreement under such right
without violating the terms of any agreement or other arrangement with any Third Party. 
 1.20 “CRC” has the
meaning set forth in Section 2.2(b). 

  
 3 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.21 “Diligent Efforts” means, with respect to a Party’s
obligation under this Agreement, the level of efforts and resources reasonably required to diligently develop, manufacture, and/or Commercialize (as applicable) each Oragenics Product in a sustained manner, consistent with the efforts and resources
a similarly situated company working in the Field would typically devote to a product of similar market potential, profit potential, strategic value and/or proprietary protection, based on market conditions then prevailing. With respect to a
particular task or obligation, Diligent Efforts requires that the applicable Party promptly assign responsibility for such task and consistently make and implement decisions and allocate resources designed to advance progress with respect to such
task or obligation. 
 1.22 “Equity Agreement” has the meaning set forth in Section 5.1. 

1.23 “Excess Product Liability Costs” has the meaning set forth in Section 9.3. 

1.24 “Executive Officer” means: (i) the Chief Executive Officer of the applicable Party, or (2) another
senior executive officer of such Party who has been duly appointed by the Chief Executive Officer to act as the representative of the Party to resolve, as the case may be, (a) a Committee dispute, provided that such appointed officer is not a
member of the applicable Committee and occupies a position senior to the positions occupied by the applicable Party’s members of the applicable Committee, or (b) a dispute described in Section 11.1. 

1.25 “FDA” has the meaning set forth in Section 8.2(d)(xiii). 

1.26 “FDA New Product Application” means a “New Drug Application” or a “Biologics License
Application” (as both of such are defined according to relevant FDA guidelines and regulations establishing the mechanisms for the submission of new drug products in the United States of America for regulatory approval prior to commercial sale
and marketing), but excluding any Supplemental FDA Applications. 
 1.27 “Field” means, irrespective of whether such
requires regulatory approval, (i) the treatment of oral mucositis in humans, (ii) the administration to humans of a trefoil factor via genetically modified bacteria (including L. lactis) for the treatment of diseases and conditions
of the oral cavity, throat, and esophagus, or (iii) both of (i) and (ii). Notwithstanding the foregoing, the Field shall exclude (a) the delivery of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, and
(b) the Prior Field. For the sake of clarity, the Field does include the amelioration of symptoms or complications of cancer (as opposed to the treatment of the cancer itself), including those symptoms or complications that are side effects of
other cancer treatments, such as, for example, the delivery of AG013 to treat oral mucositis in cancer patients. 
 1.28
“Field Infringement” has the meaning set forth in Section 6.3(b). 
 1.29 “First Commercial
Sale” means, with respect to an Oragenics Product and country, the first sale to a Third Party of such Oragenics Product in such country after any necessary regulatory approvals and any necessary pricing or reimbursement approvals have been
obtained in such country. 

  
 4 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.30 “Fully Loaded Cost” means the direct cost of the applicable
good, product or service plus indirect charges and overheads reasonably allocable to the provision of such good, product or service in accordance with US GAAP. Subject to the approval of a project and its associated budget by the JSC, Intrexon
and/or Actobiotics will bill for its respective internal direct costs incurred through the use of annualized standard full-time equivalents; such rate shall be based upon the actual fully loaded costs of those personnel of Intrexon and its
Affiliates (including Actobiotics) directly involved in the provision of such good, product or service. Intrexon may, from time to time, adjust such full-time equivalent rate based on changes to its actual fully loaded costs and will review the
accuracy of its full-time equivalent rate at least quarterly. Intrexon and Actobiotics shall provide Oragenics with reasonable documentation indicating the basis for any direct costs (including costs charged to Intrexon and/or Actobiotics by
JSC-authorized Third Party providers), indirect charges, any allocable overhead, and any such adjustment in full-time equivalent rate. 

1.31 “Initial Financing Period” has the meaning set forth in Section 10.2(e). 

1.32 “Initial Study” means a study to be conducted under the Program to determine according to pre-set criteria the
next steps with respect to the advancement of AG013 as a clinical candidate, which study, guidelines, and criteria are described in a written plan exchanged between and approved by the Parties prior to the Effective Date. 

1.33 “In-Licensed Program IP” has the meaning set forth in Section 3.8(a). 

1.34 “Information” means information, results and data of any type whatsoever, in any tangible or intangible form
whatsoever, including without limitation, databases, inventions, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, biological, chemical, biochemical,
toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and patent and other legal information or descriptions. 

1.35 “Infringement” has the meaning set forth in Section 6.3(a). 

1.36 “Intrexon Channel Technology” means Intrexon’s current and future technology directed towards the design,
identification, culturing, and/or production of genetically modified cells, including without limitation the technology embodied in the Intrexon Materials and the Intrexon IP, and specifically including without limitation the following of
Intrexon’s platform areas and capabilities: (1) UltraVector®, (2) DNA and RNA MOD engineering, (3) protein engineering, (4) transcription control chemistry, (5) genome engineering, (6) cell system engineering,
and (7) the Actobiotics IP. 
 1.37 “Intrexon Indemnitees” has the meaning set forth in Section 9.2. 

1.38 “Intrexon IP” means the Intrexon Patents and Intrexon Know-How. 

  
 5 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.39 “Intrexon Know-How” means all Information (other than Intrexon
Patents) that (a) is Controlled by Intrexon as of the Effective Date or during the Term and (b) is reasonably required or useful for Oragenics to conduct the Program. For the avoidance of doubt, the Intrexon Know-How shall include any
Information (other than Intrexon Patents) in the Channel-Related Program IP and the AG013 Regulatory Rights. 
 1.40
“Intrexon Materials” means the genetic code and associated amino acids and gene constructs, in each case that are Controlled by Intrexon, used alone or in combination and such other proprietary reagents and biological materials
including but not limited to plasmid vectors, virus stocks, cells and cell lines, antibodies, and ligand-related chemistry, in each case that are reasonably required or provided to Oragenics by or on behalf of Intrexon to conduct the Program. 

1.41 “Intrexon Patents” means all Patents that (a) are Controlled by Intrexon as of the Effective Date or during
the Term; and (b) are reasonably required or useful for Oragenics to conduct the Program. For the avoidance of doubt, the Intrexon Patents shall include any Patent in the Channel-Related Program IP. 

1.42 “Intrexon Trademarks” means those trademarks related to the Intrexon Channel Technology that are established from
time to time by Intrexon for use across its channel partnerships or collaborations. 
 1.43 “Inventions” has the
meaning set forth in Section 6.1(b). 
 1.44 “IPC” has the meaning set forth in Section 2.2(b). 

1.45 “JSC” has the meaning set forth in Section 2.2(b). 

1.46 “KFLP” means the Koski Family Limited Partnership. 

1.47 “KFLP Group” means KFLP, each of its general partners, and Beverly Koski (as sole owner of Koski Management,
Inc.). 
 1.48 “Losses” has the meaning set forth in Section 9.1. 

1.49 “Net Sales” means, with respect to any Oragenics Product, the net sales of such Oragenics Product by Oragenics,
any Affiliates of Oragenics (including without limitation net sales of Oragenics Product to a non-Affiliate sublicensee but not including net sales by such non-Affiliate sublicensee), and any Product Sublicensees as determined in accordance with
US GAAP as the gross amount invoiced on account of sales of Oragenics Product less the usual and customary discounts as determined in accordance with US GAAP. In the case of any sale for value, such as barter or counter-trade other than in an
arm’s length transaction exclusively for cash, Net Sales shall be deemed to be the net sales at which substantially similar quantities of the product are sold for cash in an arm’s length transaction in the relevant country. If Oragenics
Product is sold to any Third Party together with other products or services, the price of such 

  
 6 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
product, solely for purposes of the calculation of Net Sales, shall be deemed to be no less than the price at which such product would be sold in a similar transaction to a third party not also
purchasing the other products or services. 
 1.50 “New Indication Milestone Event” means the filing by or on behalf
of Oragenics, or an Affiliate or permitted sublicensee of Oragenics, of a Supplemental FDA Application with the FDA (or an equivalent filing with another equivalent regulatory agency) which Supplemental FDA Application seeks approval of an
indication for use of an Oragenics Product for a use other than the current regulatory-approved indication for the respective Oragenics Product. Notwithstanding the foregoing and in order to incentivize Oragenics to pursue new indications for the
product AG013 in parallel with the existing indication (as such existing indication is described in Investigational Drug Application no. 13995) for product AG013, the New Indication Milestone Event will be deemed not to have occurred if the
filed regulatory package under the prior sentence relies upon one or more human clinical trials for the specific new indication, which clinical trial(s) were conducted simultaneously and in parallel with human clinical trials underpinning the
first-approved indication for AG013. For the avoidance of doubt and clarification purposes, any occurrence of the New Indication Milestone Event shall not also be deemed the occurrence of the New Product Milestone Event or vice versa. 

1.51 “New Product Milestone Event” means the filing by or on behalf of Oragenics, or an Affiliate or permitted
sublicensee of Oragenics, of a regulatory package with the FDA or with another equivalent regulatory agency, which regulatory package seeks approval of, or seeks permission to begin human trials in support of approval of, a subject Oragenics Product
that is deemed (according to relevant FDA guidelines) to be a different drug product than the first Oragenics Product that was clinically pursued under the Program. For purposes of the New Product Milestone Event, the subject Oragenics Product shall
be deemed to be a “different” Oragenics Product from the first Oragenics Product (and thus constitute an occurrence of the New Product Milestone Event) if regulatory approval of the subject Oragenics Product must be obtained from the FDA
under a different FDA New Product Application than the first Oragenics Product. For the avoidance of doubt and clarification purposes, any occurrence of the New Product Milestone Event shall not also be deemed the occurrence of the New Indication
Milestone Event or vice versa. 
 1.52 “Oragenics Indemnitees” has the meaning set forth in Section 9.1. 

1.53 “Oragenics Independent IP” has the meaning set forth in Section 6.1(f). 

1.54 “Oragenics Product” means any product in the Field that is created, produced, developed, or identified in whole
or in part, directly or indirectly, by or on behalf of Oragenics during the Term through use or practice of Intrexon Channel Technology, Intrexon IP, Actobiotics IP, or the Intrexon Materials. For clarity, the continued development and
Commercialization of AG013 shall be pursued under the Program as an Oragenics Product. 
 1.55 “Oragenics Program
Patent” has the meaning set forth in Section 6.2(b). 

  
 7 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.56 “Oragenics Termination IP” means all Patents or other
intellectual property that Oragenics or any of its Affiliates Controls as of the Effective Date or during the Term that cover, or is otherwise necessary or useful for, the development, manufacture or Commercialization of a Reverted Product or
necessary or useful for Intrexon to operate in the Field. Notwithstanding the foregoing, Oragenics Termination IP shall not include Oragenics Independent IP. 

1.57 “Patents” means (a) all patents and patent applications (including provisional applications), (b) any
substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, requests for continued examination, confirmations, re-examinations, extensions, supplementary protection certificates and the like of the foregoing,
and (c) any foreign or international equivalents of any of the foregoing. 
 1.58 “Phase II Milestone Event”
means the first dosing of a patient by or on behalf of Oragenics, or an Affiliate or permitted sublicensee of Oragenics, in a phase II clinical trial (as such is defined by relevant FDA guidelines) for a given Oragenics Product, irrespective of
whether such occurs in the United States of America under the jurisdiction of the FDA or elsewhere under the jurisdiction of a foreign regulatory agency. 

1.59 “Phase IIb/III Milestone Event” means the first to occur for a particular Oragenics Product of (i) the
meeting of the primary endpoint by or on behalf of Oragenics, or an Affiliate or permitted sublicensee of Oragenics, in a phase IIb clinical trial (as such is defined by relevant FDA guidelines wherein the subject clinical trial endpoints are
designed to be sufficient for regulatory approval of the clinical product without a subsequent clinical phase III trial) for a given Oragenics Product, irrespective of whether such occurs in the United States of America under the jurisdiction of the
FDA or elsewhere under the jurisdiction of a foreign regulatory agency, or (ii) the meeting of the primary endpoint by or on behalf of Oragenics, or an Affiliate or permitted sublicensee of Oragenics, in a phase III clinical trial (as such is
defined by relevant FDA guidelines) for a given Oragenics Product, irrespective of whether such occurs in the United States of America under the jurisdiction of the FDA or elsewhere under the jurisdiction of a foreign regulatory agency. 

1.60 “Prior Field” means the “Field” as recited and defined in Section 1.24 of the prior
“Exclusive Channel Collaboration Agreement” dated September 30, 2013 and previously executed by and between Intrexon and Oragenics. For clarity, the use of “Field” in the prior sentence does not have the meaning ascribed in
Section 1.27 of this Agreement. 
 1.61 “Product-Specific Program Patent” means any issued Intrexon Patent
where all the claims are directed to Inventions that relate solely and specifically to Oragenics Products. In the event of a disagreement between the Parties as to whether a particular Intrexon Patent is or is not a Product-Specific Program Patent,
the Parties shall seek to resolve the issue through discussions at the IPC, provided that if the Parties are unable to resolve the disagreement, the issue shall be submitted to arbitration pursuant to Section 11.2. Any Intrexon Patent that is
subject to such a dispute shall be deemed not to be a Product-Specific Program Patent unless and 

  
 8 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
until (a) Intrexon agrees in writing that such Patent is a Product-Specific Program Patent or (b) an arbitrator or arbitration panel determines, pursuant to Article 11, that such
Intrexon Patent is a Product-Specific Program Patent. 
 1.62 “Product Sublicense” has the meaning set forth in
Section 3.2(c). 
 1.63 “Product Sublicensee” has the meaning set forth in Section 3.2(c). 

1.64 “Program” has the meaning set forth in Section 2.1(a). 

1.65 “Proposed Terms” has the meaning set forth in Section 11.2. 

1.66 “Prosecuting Party” has the meaning set forth in Section 6.2(c). 

1.67 “Recovery” has the meaning set forth in Section 6.3(f). 

1.68 “Regulatory Approval Application Milestone Event” means for a given Oragenics Product, the first to occur of
(a) the filing by Oragenics, an Affiliate thereof, or a permitted sublicensee thereof, of an FDA New Product Application with the FDA seeking approval of such Oragenics Product, or (b) the filing of an equivalent approval or marketing
application for such Oragenics Product with an equivalent regulatory authority in a foreign jurisdiction. 
 1.69 “Retained
Product” has the meaning set forth in Section 10.4(a). 
 1.70 “Reverse Merger” means the sale of
Oragenics, whether in a single transaction or in a series of related transactions that are consummated contemporaneously (or consummated pursuant to contemporaneous agreements), to one or more Third Parties on an arm’s length basis, pursuant to
which such Third Party or Third Parties acquire(s) via merger more than fifty percent (50%) of Oragenics’ common stock in a form of transaction wherein Oragenics is the surviving entity. 

1.71 “Reverted Product” has the meaning set forth in Section 10.4(c). 

1.72 “SEC” means the United States Securities and Exchange Commission. 

1.73 “Sublicensing Revenue” means any cash consideration, or the cash equivalent value of non-cash consideration,
regardless of whether in the form of upfront payments, milestones, or royalties, actually received by Oragenics or its Affiliate from a Third Party in consideration for a grant of a sublicense under the Intrexon IP or any rights to develop or
Commercialize Oragenics Products, but excluding: (a) any amounts paid as bona fide reimbursement for research and development costs to the extent incurred following such grant; (b) bona fide loans or any payments in consideration for a
grant of equity of Oragenics to the extent that such consideration is equal to or less than fair market value (i.e. any amounts in excess of fair market value shall be Sublicensing Revenue); (c) any amounts paid by Oragenics


  
 9 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
to a Third Party for the right to operate under or utilize Third Party owned intellectual property that is used to make or use an Oragenics Product underlying the Sublicensing Revenue,
(d) subject to the waiver provisions of Section 5.2(c), any payments received by Oragenics from permitted sublicensees for the achievement of a Commercialization Milestone Event that is the same as (or substantially similar to) a
Commercialization Milestone Event for which Intrexon is entitled to receive an equity-based milestone payment under Section 5.2(a), and (e) amounts received from sublicensees in respect of any Oragenics Product sales that are included in
Net Sales and for which Intrexon receives revenue sharing payments under Section 5.4(a). For clarity, Sublicensing Revenue includes milestone payments for Oragenics Products received by Oragenics from a sublicensee of Oragenics (including a
Product Sublicensee) for (i) the achievement by the Oragenics sublicensee of any milestone event that is not the same as, or substantially similar to, a Commercialization Milestone Event, (ii) the achievement by the Oragenics sublicensee
of the second or subsequent occurrence of the same (or substantially similar) Commercialization Milestone Event, irrespective of whether the first occurrence of the Commercialization Milestone Event in question was achieved by Oragenics, or its
Affiliate or a sublicensee, and (iii) the achievement by a permitted sublicensee of Oragenics of the first occurrence of the same (or substantially similar) Commercialization Milestone Event where Intrexon elects to share such milestone payment
as Sublicensing Revenue in accord with Section 5.2(c). 
 1.74 “Sublicensing Revenue Rate” means a percentage
of Sublicensing Revenue applicable to a proposed sublicense by Oragenics as follows: (a) with respect to any sublicense of an AG013 Oragenics Product (including new indications thereof), any revenues Oragenics receives from a Product
Sublicensee under a Product Sublicense that are not a percentage of Product Sublicensee’s Net Sales of Oragenics Products, and any amounts recovered under Section 6.3(f), the Sublicensing Revenue Rate shall be fifty percent (50%); and
(b) with respect to any other sublicense, the Sublicensing Revenue Rate shall be determined in accordance with Section 3.2. 

1.75 “Superior Therapy” means a therapy in the Field that, based on the data then available, (a) demonstrably
appears to offer either superior efficacy or safety or significantly lower cost of therapy, as compared with both (i) those therapies that are marketed (either by Oragenics or others) at such time for the indication and (ii) those
therapies that are being actively developed by Oragenics for such indication; (b) demonstrably appears to represent a substantial improvement over such existing therapies; and (c) has intellectual property protection and a regulatory
approval pathway that, in each case, would not present a significant barrier to commercial development. 
 1.76 “Supplemental
FDA Application” means a “Supplemental New Drug Application” or a “Supplemental Biologics License Application” (as both of such are defined according to relevant FDA guidelines and regulations establishing the mechanisms
for the submission of data in support of the FDA granting approval for new, amended, and/or expanded label indications for a prior-approved drug product in the United States of America). 

  
 10 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.77 “Supplemental In-Licensed Third Party IP” has the meaning set
forth in Section 3.8(a). 
 1.78 “Support Memorandum” has the meaning set forth in Section 11.2. 

1.79 “Technology Access Fee” has the meaning set forth in Section 5.1. 

1.80 “Term” has the meaning set forth in Section 10.1. 

1.81 “Territory” means the entire world. 

1.82 “Third Party” means any individual or entity other than the Parties or their respective Affiliates. 

1.83 “Third Security” means Third Security, LLC. 

1.84 “US GAAP” means generally accepted accounting principles in the United States. 

1.85 “Work Plan” has the meaning set forth in Section 2.1(c). 

ARTICLE 2 

SCOPE OF CHANNEL COLLABORATION; MANAGEMENT 

2.1 Direction of the Program. 

(a) Generally. The general purpose of the channel collaboration described in this Agreement will be to use the Intrexon Channel
Technology to research, develop and Commercialize products for use in the Field, including the continued development and Commercialization of AG013 (collectively, the “Program”). As provided below, the JSC shall establish, monitor,
and govern projects for the Program. Either Party may propose other potential projects in the Field for review and consideration by the JSC. 

(b) Advancement of AG013; the Initial Study. The Parties have concluded that the Program would benefit from the Initial Study being
conducted before further other clinical activity is pursued for AG013, and, as such, have agreed that the Initial Study shall be conducted by Intrexon and/or Actobiotics under Section 4.7 immediately following the Effective Date. Exhibit
A contains a general description of the Initial Study, and Intrexon shall supply to Oragenics a complete study plan, in agreement with the parameters (including timing, budget, data evaluation criteria, and resulting implications with respect to
subsequent AG013 clinical activity) set forth in Exhibit A, for the Initial Study prior to commencement of the study. Following the completion of the Initial Study, the JSC will promptly meet and review the data produced under the Initial
Study and apply the criteria set forth in Exhibit A, with the purpose of determining the immediate clinical path forward for AG013 under the Program. 

  
 11 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (c) Management via Work Plan. The Parties shall mutually draft and finalize at the
JSC, within thirty (30) days following completion of the Initial Study an initial version of a Program-wide work plan describing the development of Oragenics Products, including advancement of AG013 as an Oragenics Product, in the Field
(“Work Plan”), which Work Plan shall be adopted by the JSC. The Work Plan shall serve as a basis for the operation of the Program on a going-forward basis, and may be modified by the JSC subject to the rest of this Article 2,
including to introduce parallel research projects for the collaborative pursuit of new indications for AG013 and/or of new Oragenics Products in the Field. Notwithstanding the foregoing, the Parties (i) agree to conduct the Initial Study under
the Program beginning immediately after the Effective Date, and (ii) commit to have the JSC meet regularly prior to the finalization of the Work Plan in order to conduct and monitor, and to review the results of, the Initial Study in accord
with Section 2.1(b) above and to discuss other issues of relevance to the Program. 
 2.2 Committees. 

(a) Generally. The Parties desire to establish several committees (collectively, “Committees”) to oversee the Program
and to facilitate communications between the Parties with respect thereto. Each of such Committees shall have the responsibilities and authority allocated to it in this Article 2. Each of the Committees shall have the obligation to exercise its
authority consistent with the respective purpose for such Committee as stated herein and any such decisions shall be made in good faith. 

(b) Formation and Purpose. Promptly following the Effective Date, the Parties shall confer and then create the JSC and the IPC, and,
optionally, create one or more of the other Committees listed in the chart below. Each Committee shall have the purpose indicated in the chart. To the extent that after conferring both Parties agree to not create a Committee (other than the JSC and
the IPC), the creation of such Committee shall be deferred until one Party informs the other Party of its then desire to create the so-deferred Committee, at which point the Parties will thereafter promptly create the so-deferred Committee and
promptly schedule a meeting of such Committee within a reasonable time. 
  

			
	 Committee
	  	 Purpose

	Joint Steering Committee (“JSC”)	  	Establish projects for the Program and establish the priorities, as well as approve budgets for such projects. Approve all subcommittee projects and plans.
		
	Chemistry, Manufacturing and Controls Committee (“CMCC”)	  	Establish project plans and review and approve activities and budgets for chemistry, manufacturing, and controls under the Program.


  
 12 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  


			
	 Committee
	  	 Purpose

	Clinical/Regulatory Committee (“CRC”)	  	Review and approve all research and development plans and projects, including clinical projects, associated with any necessary regulatory approvals, all associated publications, and all regulatory filings and correspondence relating
to gaining regulatory approval under the Program; and review and approve itemized budgets with respect to the foregoing.
		
	Commercialization Committee (“CC”)	  	Establish project plans and review and approve activities and budgets for Commercialization activities under the Program.
		
	Intellectual Property Committee (“IPC”)	  	Evaluate intellectual property issues in connection with the Program; review and approve itemized budgets with respect to the foregoing.

 2.3 General Committee Membership and Procedure. 

(a) Membership. For each Committee, each Party shall designate an equal number of representatives (not to exceed four (4) for each
Party) with appropriate expertise to serve as members of such Committee. For the JSC the representatives must all be employees of such Party or an Affiliate of such Party, and for Committees other than the JSC the representatives must all be
employees of such Party or an Affiliate of such Party with the caveat that each Party may designate for each such other Committee up to one (1) representative who is not an employee if: (i) such non-employee representative agrees in
writing to be bound to the terms of this Agreement for the treatment and ownership of Confidential Information and Inventions of the Parties, and (ii) the other Party consents to the designation of such non-employee representative, which
consent shall not be unreasonably withheld. Each representative as qualified above may serve on more than one (1) Committee as appropriate in view of the individual’s expertise. Each Party may replace its Committee representatives at any
time upon written notice to the other Party. Each Committee shall have a chairperson; the chairperson of each committee shall serve for a two-year term and the right to designate which representative to the Committee will act as chairperson shall
alternate between the Parties, with Oragenics selecting the chairperson first for the JSC, CRC and CC, and Intrexon selecting the chairperson first for the CMCC and IPC. The chairperson of each Committee shall be responsible for calling meetings,
preparing and circulating an agenda in advance of each meeting of such Committee, and preparing and issuing minutes of each meeting within fifteen (15) days thereafter. 

  
 13 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (b) Meetings. Each Committee shall hold meetings at such times as it elects to do so,
but in no event shall such meetings be held less frequently than once every six (6) months, with the caveat that both Parties may agree to suspend activities of a given Committee other than the JSC until such time as one Party informs the other
Party of its then desire to reactivate the so-suspended Committee, at which point the Parties will thereafter schedule and hold the next meeting for the reactivated Committee within one (1) month. Meetings of any Committee may be held in person
or by means of telecommunication (telephone, video, or web conferences). To the extent that a Committee holds any meetings in person, the Parties will alternate in designating the location for such in-person meetings, with Oragenics selecting the
first meeting location for each Committee. A reasonable number of additional representatives of a Party may attend meetings of a Committee in a non-voting capacity. Each Party shall be responsible for all of its own expenses of participating in any
Committee excepting that an Intrexon employee or agent serving on a Committee shall not prevent Intrexon from recouping the Fully Loaded Costs otherwise derived from the labor of that employee or agent in the course of providing manufacturing or
support services as set forth in Sections 4.6 and 4.7 below. 
 (c) Meeting Agendas. Each Party will disclose to the other proposed
agenda items along with appropriate information at least three (3) business days in advance of each meeting of the applicable Committee; provided, that a Party may provide its agenda items to the other Party within a lesser period of time in
advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence of a specific agenda for such Committee meeting.

 (d) Limitations of Committee Powers. Each Committee shall have only such powers as are specifically delegated to it hereunder or
from time to time as agreed to in writing by the mutual consent of the Parties and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, no Committee shall have any power to amend this Agreement.
Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 12.7 below. Additionally, no member of any Committee shall be able to vote in such Committee and thereby bind its respective Party on any
material matter except as otherwise properly authorized, approved, or delegated by such Party in accord with Section 2.5. 
 2.4
Committee Decision-Making. If a Committee is unable to reach unanimous consent on a particular matter within thirty (30) days of its initial consideration of such matter, then either Party may provide written notice of such dispute to the
Executive Officer of the other Party. The Executive Officers of each of the Parties will meet at least once in person or by means of telecommunication (telephone, video, or web conferences) to discuss the dispute and use their good faith efforts to
resolve the dispute within thirty (30) days after submission of such dispute to the Executive Officers. If any such dispute is not resolved by the Executive Officers within thirty (30) days after submission of such dispute to such
officers, then the Executive Officer of the Party specified in the applicable subsection below shall have the authority to finally resolve such dispute acting in good faith. 

(a) Casting Vote at JSC. If a dispute at the JSC is not resolved pursuant to Section 2.4 above, then the Executive Officer of
Oragenics shall have the authority to finally resolve such dispute. 

  
 14 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (b) Casting Vote at CMCC. If a dispute at the CMCC is not resolved pursuant to
Section 2.4 above, then (i) in the case of any disputes relating to the Intrexon Materials, the manufacture of an Oragenics Product active pharmaceutical ingredient, or the manufacturing of other components of Oragenics Products contracted
for or manufactured by Intrexon, the Executive Officer of Intrexon shall have the authority to finally resolve such dispute; and (ii) in the case of any other disputes, the Executive Officer of Oragenics shall have the authority to finally
resolve such dispute. 
 (c) Casting Vote at CRC. If a dispute at the CRC is not resolved pursuant to Section 2.4 above, then
the Executive Officer of Oragenics shall have the authority to finally resolve such dispute. 
 (d) Casting Vote at CC. If a dispute
at the CC is not resolved pursuant to Section 2.4 above, then the Executive Officer of Oragenics shall have the authority to finally resolve such dispute. 

(e) Casting Vote at IPC. If a dispute at the IPC is not resolved pursuant to Section 2.4 above, then the Executive Officer of
Intrexon shall have the authority to finally resolve such dispute, provided that such authority shall be shared by the Parties with respect to Product-Specific Program Patents (i.e., neither Party shall have the casting vote on such matters, and any
such disputes shall be resolved pursuant to Article 11). 
 (f) Other Committees. If any additional Committee other than those set
forth in Section 2.2(b) is formed, then the Parties shall, at the time of such formation, agree on which Party shall have the authority to finally resolve a dispute that is not resolved pursuant to Section 2.4 above. 

(g) Restrictions. Neither Party shall exercise its right to finally resolve a dispute at a Committee in accordance with this
Section 2.4 in a manner that (i) excuses such Party from any of its obligations specifically enumerated under this Agreement; (ii) expands the obligations of the other Party under this Agreement; (iii) negates any consent rights
or other rights specifically allocated to the other Party under this Agreement; (iv) purports to resolve any dispute involving the breach or alleged breach of this Agreement; (v) resolves a matter if the provisions of this Agreement
specify that mutual agreement is required for such matter; or (vi) would require the other Party to perform any act that is inconsistent with applicable law. 

2.5 Authorization of Committee Representatives. Each representative serving on a Committee shall be responsible for ensuring that he or
she acts only as duly authorized by its respective Party and obtains any advance approvals, delegations, or other authorizations from his or her respective Party in advance of making any Committee votes. Any Committee representative shall only be
able to bind its respective appointing Party via any Committee vote 

  
 15 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
or other material Committee activity to the extent such vote or other activity has been previously approved by the Party, is within the authority duly delegated to the representative by the
respective Party, or is otherwise authorized by its respective Party as may be required by that Party’s corporate charter or bylaws, or by its board of directors. Any action or vote taken without valid authority shall be considered null and
void and shall be without effect unless subsequently approved by a vote in accord with this Section 2.5. 
 ARTICLE 3 

LICENSE GRANTS 

3.1 Licenses to Oragenics. 

(a) Subject to the terms and conditions of this Agreement, Intrexon and Actobiotics hereby grant to Oragenics a license under the
Intrexon IP and the Actobiotics IP to research, develop, use, import, export, make, have made, sell, and offer for sale Oragenics Products in the Field in the Territory. Such license shall be exclusive (even as to Intrexon and Actobiotics) with
respect to any clinical development, selling, offering for sale or other Commercialization of Oragenics Products in the Field, and shall be otherwise non-exclusive. 

(b) Subject to the terms and conditions of this Agreement, Intrexon and Actobiotics hereby grant to Oragenics a non-exclusive,
royalty-free license to use and display the Intrexon Trademarks and Actobiotics trademarks, solely in connection with the Commercialization of Oragenics Products, in the promotional materials, packaging, and labeling for Oragenics Products, as
provided under and in accordance with Section 4.9. 
 (c) Subject to the terms and conditions of this Agreement, Intrexon and
Actobiotics hereby grant to Oragenics an exclusive license in the Field under the AG013 Regulatory Rights, including an exclusive right in the Field to make reference to for purposes of conducting clinical trials and obtaining regulatory approval
for AG013 as an Oragenics Product. 
 3.2 Sublicensing. Except as provided in this Section 3.2, Oragenics shall not sublicense
the rights granted under Section 3.1 to any Third Party, or transfer the Intrexon Materials to any Third Party, or otherwise grant any Third Party the right to research, develop, use, or Commercialize Oragenics Products or use or display the
Intrexon Trademarks, in each case except with Intrexon’s written consent, which written consent may be withheld in Intrexon’s sole discretion. The parties shall agree, in connection with any such sublicense not covered under Sections
3.2(a) through 3.2(c) below, on the applicable Sublicensing Revenue Rate with respect to such sublicense. Notwithstanding the foregoing, Oragenics (and its Product Sublicensees only to the extent set forth in Section 3.2(a) below) shall have a
limited right to sublicense under the circumstances described in Sections 3.2(a) through 3.2(c) below. 
 (a) Oragenics may transfer,
to the extent reasonably necessary and after providing Intrexon with reasonable advance notice thereof, Intrexon Materials that are or that produce Oragenics Products to a Third Party contractor performing contract manufacturing


  
 16 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
responsibilities for Oragenics Products, and may in connection therewith grant limited sublicenses necessary to enable such Third Party to perform such activities. If Oragenics transfers any
Intrexon Materials under this Section 3.2(a), Oragenics will remain obligated to ensure that the rights of Intrexon in and to the Intrexon Materials and Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are not violated
by any such Third Party contractor. A Product Sublicensee of Oragenics may transfer, to the extent reasonably necessary and upon the consent of Intrexon, which consent shall not be unreasonably withheld, Intrexon Materials that are or that produce
ingredients for the Oragenics Product sublicensed by the Product Sublicensee to a Third Party contractor performing on behalf of that Product Sublicensee contract manufacturing responsibilities for Oragenics Products, and may in connection therewith
grant limited sublicenses to the extent necessary to enable such Third Party to perform such activities. Oragenics will require and ensure that if any Product Sublicensee transfers any Intrexon Materials under this Section 3.2(a), that such
Product Sublicensee, after obtaining Intrexon’s consent, will take commercially reasonable steps, including contractually obligating any such Third Party contractors, to ensure that the rights of Intrexon in and to the Intrexon Materials and
Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are not violated by any Third Party contractors of such Product Sublicensees. 

(b) Oragenics may, with Intrexon’s written consent, which written consent shall not be unreasonably withheld, conditioned, or
delayed, sublicense the rights granted under Section 3.1 to an Affiliate, or transfer the Intrexon Materials to an Affiliate, or grant an Affiliate the right to use or display the Intrexon Trademarks. In the event that Intrexon consents to any
such grant or transfer to an Affiliate, Oragenics shall remain responsible for, and be guarantor of, the performance by any such Affiliate and shall cause such Affiliate to comply with the provisions of this Agreement in connection with such
performance (as though such Affiliate were Oragenics), including any payment obligations owed to Intrexon hereunder. 
 (c) Oragenics
may grant a sublicense of the rights granted under Section 3.1 (and not including a right to sublicense under this Section 3.2(c)) to a Third Party licensee of any Oragenics Product that is the subject of an effective Investigational New
Drug Application or equivalent application or investigational exemption with a foreign regulatory body (a “Product Sublicensee”) to the extent necessary to permit such Third Party to research, develop, use, import, export, make,
have made, sell, and offer for sale that Oragenics Product (a “Product Sublicense”), provided, that (i) such Product Sublicense is expressly limited to the appropriate Oragenics Product, (ii) such Product Sublicensee does
not grant the Product Sublicensee any rights to Intrexon IP other than that incorporated into the Oragenics Product at the time of the Product Sublicense, (iii) does not purport to relieve Oragenics of any of its obligations under this
Agreement, (iv) the Product Sublicensee agrees in writing, in a document in form reasonably acceptable to Intrexon and to which Intrexon is an express third party beneficiary, to abide by the following provisions of this Agreement: Sections
3.1., 3.3-3.6, 3.8, 3.10, and 3.11 and Articles 6, 7, and 10, (v) the Product Sublicense is presented in full to the JSC by Oragenics before execution by Oragenics and the prospective Product Sublicensee and as soon as is reasonably practical
for the purpose of allowing the JSC to review and comment upon the terms and scope of the Product Sublicense agreement before execution, and (vi) the Product Sublicensee is not controlled by or otherwise affiliated with a member of the KFLP
Group. 

  
 17 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 3.3 Limitation on Sublicensees. None of the enforcement rights under the Intrexon
Patents that are granted to Oragenics pursuant to Section 6.3 shall be transferred to, or exercised by, a sublicensee except with Intrexon’s prior written consent, which may be withheld in Intrexon’s sole discretion. 

3.4 No Non-Permitted Use. Oragenics hereby covenants that it shall not, nor shall it permit any Affiliate or, if applicable,
(sub)licensee, to use or practice, directly or indirectly, any Intrexon IP, Intrexon Channel Technology, or Intrexon Materials for any purposes other than those expressly permitted by this Agreement. 

3.5 Exclusivity. Intrexon, Actobiotics and Oragenics mutually agree that, under the channel collaboration established by this
Agreement, it is intended that the Parties will be exclusive to each other in the Field. To this end, neither Intrexon, Actobiotics, nor its Affiliates shall make the Intrexon Channel Technology, Intrexon Materials or Actobiotics IP available to any
Third Party for the purpose of developing or Commercializing products in the Field, and neither Intrexon nor any Affiliate shall pursue (either by itself or with a Third Party or Affiliate) the research, development or Commercialization of any
product for purpose of sale in the Field, outside of the Program. Further, other than Oragenics’ activities within the Program, neither Oragenics nor its Affiliates shall pursue (either by itself or with a Third Party or Affiliate) the
research, development or Commercialization of any product that uses, incorporates, references in a related regulatory filing, or is produced from Intrexon Channel Technology, Intrexon Materials, or Intrexon IP for purpose of sale in the Field. 

3.6 Off Label Use. For purpose of clarity, (a) following the First Commercial Sale of an Oragenics Product, the use by direct or
indirect purchasers or other users of Oragenics Products outside the Field (i.e. “off label use”) shall not constitute a breach by Oragenics of the terms of Section 3.4 or 3.5, provided that neither Oragenics nor its Affiliate (nor
any Third Party under contract with either of them) marketed or promoted Oragenics Products for such off-label use; and (b) following the First Commercial Sale of a product by Intrexon, an Intrexon Affiliate, or a Third Party sublicensee,
collaborator, or partner of Intrexon, the use by direct or indirect purchasers or other users of such products in the Field (i.e. “off label use”) shall not constitute a breach by Intrexon of the terms of Section 3.5, provided that
neither Intrexon nor its Affiliate (nor any Third Party under contract with either of them) marketed or promoted such products for such off-label use. 

3.7 No Prohibition on Intrexon. Except as explicitly set forth in Sections 3.1 and 3.5, nothing in this Agreement shall prevent
Intrexon from practicing or using the Intrexon Materials, Intrexon Channel Technology, and Intrexon IP for any purpose, and to grant to Third Parties the right to do the same. Without limiting the generality of the foregoing, Oragenics acknowledges
that Intrexon has all rights, in Intrexon’s sole discretion, to make the Intrexon Materials, Intrexon Channel Technology (including any biological materials used in an Oragenics Product), and Intrexon IP available to Third Party channel
partners or collaborators for use in fields outside the Field. 

  
 18 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 3.8 Rights to Clinical and Regulatory Data. With the exception of the AG013 Regulatory
Rights, Oragenics shall own and control all clinical data and regulatory filings relating to Commercialization of Oragenics Products (except to the extent such become Reverted Products). Oragenics shall provide (or shall cause any applicable Product
Sublicensee to provide) full copies of all clinical and non-clinical data and reports, regulatory filings, and communications from regulatory authorities that relate specifically and solely to Oragenics Products. To the extent that there exist any
clinical and non-clinical data and reports, regulatory filings, and communications from regulatory authorities owned by Oragenics (or a Product Sublicensee) that relate both to Oragenics Products and other products produced by Oragenics (or a
Product Sublicensee) outside the Field, Oragenics shall provide (or shall cause any applicable Product Sublicensee to provide) to Intrexon upon Intrexon’s request copies of the portions of such data, reports, filings, and communications that
relate to Oragenics Products. Subject to its ongoing obligations of exclusivity under Section 3.5, Intrexon shall be permitted, directly or in conjunction with or through partners or other channel collaborators, to reference this data, reports,
filings, and communications relating to Oragenics Products in regulatory filings made to obtain regulatory approval for products indicated for use in fields outside the Field. Intrexon shall have the right to use any such information in developing
and Commercializing products outside the Field and to license any Third Parties to do so. 
 3.9 Third Party Licenses. 

(a) [*****] shall obtain, at its sole expense, any licenses from Third Parties that are required in order to practice the Intrexon
Channel Technology in the Field where the licensed intellectual property is reasonably necessary for [*****] to conduct genetic and cell engineering and related analytic activities under JSC established plans for the Program (but excluding
intellectual property directed to any specific target genes, cells lines or genetic transformation methodologies) (“Supplemental In-Licensed Third Party IP”). Other than with respect to Supplemental In-Licensed Third Party IP,
[*****] shall be solely responsible for obtaining [*****] any licenses from Third Parties that [*****] determines, in its sole discretion, are required in order to lawfully make, use, sell, offer for sale, or import Oragenics
Products (“Complementary In-Licensed Third Party IP”). Supplemental In-Licensed Third Party IP and Complementary In-Licensed Third Party IP are collectively referred to as “In-Licensed Program IP”. 

(b) In the event that either Party desires to license from a Third Party any Supplemental In-Licensed Third Party IP or Complementary
In-Licensed Third Party IP, such Party shall so notify the other Party, and the IPC shall discuss such In-Licensed Program IP and its applicability to the Oragenics Products and to the Field. As provided above in Section 3.9(a), [*****]
shall have the sole right and responsibility to pursue a license under Supplemental In-Licensed Third Party IP, and [*****] hereby covenants that it shall not itself directly license such Supplemental In-Licensed Third Party IP at any time,
provided that [*****] may (but shall 

  
 19 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
not be obligated to) obtain such a license directly if the Third Party owner or licensee of such Supplemental In-Licensed Third Party IP brings an infringement action against [*****] or
its Affiliates or threatens to bring such action (solely to the extent such threats would reasonably be considered to subject the Third Party owner or licensee to declaratory judgment action jurisdiction) and, after written notice to [*****]
of such action, [*****] fails to obtain a license to such Supplemental In-Licensed Third Party IP using Diligent Efforts within ninety (90) days after such notice. Following the IPC’s discussion of any Complementary In-Licensed
Third Party IP, subject to Section 3.9(c), [*****] shall have the right to pursue a license under Complementary In-Licensed Third Party IP, at [*****] sole expense. For the avoidance of doubt, [*****] may at any time obtain
a license under Complementary In-Licensed Third Party IP outside the Field, at [*****] sole expense, provided that if [*****] decides to seek to obtain such a license, it shall use reasonable efforts to coordinate its
licensing activities in this regard with [*****]. 
 (c) [*****] shall provide the proposed terms of any license under
Complementary In-Licensed Third Party IP and the final version of the definitive license agreement for any Complementary In-Licensed Third Party IP to the IPC for review and discussion prior to signing, and shall consider [*****] comments
thereto in good faith. To the extent that [*****] obtains a license under Supplemental In-Licensed Third Party IP, [*****] shall provide the final version of the definitive license agreement for such Supplemental In-Licensed Third
Party IP to the IPC. If [*****] acquires rights under any In-Licensed Program IP outside the Field, it will do so on a non-exclusive basis unless it obtains the prior written consent of [*****] for such license outside the Field to be
exclusive. Any Party that is pursuing a license to any In-Licensed Program IP with respect to the Field under this Section 3.9 shall keep the other Party reasonably informed of the status of any negotiations relating thereto. For purposes of
clarity, (i) any costs incurred by [*****] in obtaining and maintaining licenses to Supplemental In-Licensed Third Party IP shall be borne solely by [*****], and (ii) any costs incurred by [*****] in obtaining and
maintaining licenses to Complementary In-Licensed Third Party IP (and, to the limited extent provided in subsection (b), Supplemental In-Licensed Third Party IP) shall be borne solely by [*****]. 

(d) For any Third Party license under which Oragenics or its Affiliates obtain a license under Patents claiming inventions or know-how
specific to or used or incorporated into the development, manufacture, and/or Commercialization of Oragenics Products, Oragenics shall use commercially reasonable efforts to ensure that Oragenics will have the ability, pursuant to
Section 10.4(h), to assign such agreement to Intrexon or grant a sublicense to Intrexon thereunder (having the scope set forth in Section 10.4(h)). 

(e) The licenses granted to Oragenics under Section 3.1 may include sublicenses under Intrexon IP that has been licensed to
Intrexon by one or more Third Parties. Any such sublicenses are subject to the terms and conditions set forth in the applicable upstream license agreement, subject to the cost allocation set forth in Section 3.9(c), provided that
Intrexon shall either provide unredacted copies of such upstream license agreements to Oragenics or shall disclose in writing to Oragenics all of such terms and conditions that are applicable to Oragenics.


  
 20 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
Oragenics shall not be responsible for complying with any provisions of such upstream license agreements unless, and to the extent that, such provisions have been disclosed to Oragenics as
provided in the preceding sentence. 
 (f) If either Party receives notice from a Third Party concerning activities of a Party taken
in conjunction with performance of obligations under this Agreement, which notice alleges infringement by a Party of, or offers license under, Patents or other intellectual property rights owned or controlled by that Third Party, the receiving Party
shall inform the other party thereof within five (5) business days. 
 3.10 Licenses to Intrexon. Subject to the terms and
conditions of this Agreement, Oragenics hereby grants to Intrexon a non-exclusive, worldwide, fully-paid, royalty-free license, under any applicable Patents or other intellectual property Controlled by Oragenics or its Affiliates, solely to the
extent necessary for Intrexon to conduct those responsibilities assigned to it under this Agreement, which license shall be sublicensable solely to Intrexon’s Affiliates or to any Intrexon subcontractors as permitted in accord with
Section 4.6 or as otherwise permitted to be used by Intrexon in conjunction with support services under Section 4.7 (subject to JSC research plan approval) 

3.11 Restrictions Relating to Intrexon Materials. Oragenics and its permitted sublicensees shall use the Intrexon Materials solely for
purposes of the Program and not for any other purpose without the prior written consent of Intrexon. With respect to the Intrexon Materials comprising Intrexon’s vector assembly technology, Oragenics shall not, and shall ensure that Oragenics
personnel and permitted sublicensees do not, except as otherwise expressly permitted under this Agreement, (a) distribute, sell, lend or otherwise transfer such Intrexon Materials to any Third Party; (b) co-mingle such Intrexon Materials
with any other proprietary biological or chemical materials without Intrexon’s written consent; or (c) analyze such Intrexon Materials or in any way attempt to reverse engineer or sequence such Intrexon Materials. 

ARTICLE 4 

OTHER RIGHTS AND OBLIGATIONS 

4.1 Development and Commercialization. Subject to Sections 4.6 and 4.7, Oragenics shall be solely responsible for the development and
Commercialization of Oragenics Products in the Field. Oragenics shall be responsible for all costs incurred in connection with the Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing
capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating
the Fully Loaded Cost of manufacturing an Oragenics Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and
amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform 

  
 21 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of an Oragenics Product (which research costs shall be
reimbursed by Oragenics); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within clause (a) of the previous sentence shall include the scale-up of Intrexon Materials
for generating data for regulatory approval submissions and Commercialization of Oragenics Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third
Party contractors retained by either Intrexon or Oragenics (with Intrexon’s consent). 
 4.2 Transfer of Technology and
Information. The JSC shall develop a plan and protocol for each project and timing for the transfer of relevant data and Intrexon Materials. 

4.3 Information and Reporting. Oragenics will keep Intrexon informed about Oragenics’ efforts to develop and Commercialize
Oragenics Products, including reasonable and accurate summaries of Oragenics’ (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans,
global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization of the Oragenics Products,
including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product safety event, receipt of
regulatory approval or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Oragenics shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical
protocols and reports, and regulatory correspondence and filings generated by Oragenics as soon as practical after they become available. Intrexon will keep Oragenics informed about Intrexon’s efforts (a) to establish manufacturing
capabilities and facilities for Oragenics Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Program with
respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 above, such disclosures by Oragenics and Intrexon will be coordinated by the JSC and made in
connection with JSC meetings at least once every six (6) months while Oragenics Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings. 

4.4 Regulatory Matters. At all times after the Effective Date, Oragenics shall own and maintain, at its own cost, all regulatory
filings and regulatory approvals for Oragenics Products that Oragenics is developing or Commercializing pursuant to this Agreement. As such, Oragenics shall be responsible for reporting all adverse events related to such Oragenics Products to the
appropriate regulatory authorities in the relevant countries, in accordance with the applicable laws and regulations of such countries. To the extent that Intrexon will itself develop, or in collaboration with other third parties develop, Intrexon
Materials outside of the Field, Intrexon may request that Oragenics and Intrexon establish and execute a separate safety data exchange agreement, which agreement will address and govern the timely exchange of


  
 22 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
safety information generated by Oragenics, Intrexon, and relevant third parties with respect to specific Intrexon Materials. The decision to list or not list Patents in any regulatory filing for
an Oragenics Product (for example, as required by 21 C.F.R. § 314.53(b)), add or delete a Patent from a regulatory filing, or to otherwise identify a Patent to a third party in compliance with laws or regulations relating to regulatory
approvals (for example, in compliance with 42 U.S.C. § 262(a)(1)(A)(k) et seq.) shall be determined by Intrexon, after consultation with Oragenics, except with respect to Product Specific Program Patents, which will be mutually
determined by the Parties. 
 4.5 Diligence. 

(a) Oragenics shall use, and shall require its Product Sublicensees to use, Diligent Efforts to develop and Commercialize Oragenics
Products. 
 (b) Without limiting the generality of the foregoing, Intrexon may, from time to time, notify Oragenics that it believes
it has identified a Superior Therapy, and in such case Intrexon shall provide to Oragenics its then-available information about such therapy and reasonable written support for its conclusion that the therapy constitutes a Superior Therapy. Oragenics
shall have the following obligations with respect to such proposed Superior Therapy: (i) within sixty (60) days after such notification, Oragenics shall prepare and deliver to the JSC for review and approval a development plan detailing
how Oragenics will pursue the Superior Therapy (including a proposed budget); (ii) Oragenics shall revise the development plan as directed by the JSC; and (iii) following approval of the development plan by the JSC, Oragenics shall use
Diligent Efforts to pursue the development of the Superior Therapy under the Program in accordance with such development plan. If Oragenics fails to comply with the foregoing obligations, or if Oragenics unreasonably exercises its casting vote at
the JSC to either (x) prevent the approval of a development plan for a Superior Therapy; (y) delay such approval more than sixty (60) days after delivery of the development plan to the JSC; or (z) approve a development plan that
is insufficient in view of the nature and magnitude of the opportunity presented by the Superior Therapy, then Intrexon shall have the termination right set forth in Section 10.2(c) (subject to the limitation set forth therein). For clarity,
any dispute arising under this 4.5, including any dispute as to whether a proposed project constitutes a Superior Therapy (as with any other dispute under this Agreement) shall be subject to dispute resolution in accordance with Article 11. 

(c) The activities of Oragenics’ Affiliates and any permitted sublicensees shall be attributed to Oragenics for the purposes of
evaluating Oragenics’ fulfillment of the obligations set forth in this Section 4.5. 
 4.6 Manufacturing. Intrexon shall
have the option and, in the event it so elects, shall use Diligent Efforts, to perform any manufacturing activities in connection with the Program that relate to the Intrexon Materials, including through the use of a suitable Third Party contract
manufacturer. To the extent that Intrexon so elects, Intrexon may request that Oragenics and Intrexon establish and execute a separate manufacturing and supply agreement, which 

  
 23 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
agreement will establish and govern the production, quality assurance, and regulatory activities associated with manufacture of Intrexon Materials. Except as provided in Section 4.1, any
manufacturing undertaken by Intrexon pursuant to the preceding sentence shall be performed in exchange for cash payments equal to Intrexon’s Fully Loaded Cost in connection with such manufacturing, on terms to be negotiated by the Parties in
good faith. In the event that Intrexon does not manufacture Intrexon Materials, bulk drug product or bulk quantities of other components of Oragenics Products, then Intrexon shall provide to Oragenics or a contract manufacturer selected by Oragenics
and approved by Intrexon all Information Controlled by Intrexon that is (a) related to the manufacturing of such Intrexon Materials, bulk drug product or bulk qualities of other components of Oragenics Products, for use in the Field and
(b) reasonably necessary to enable Oragenics or such contract manufacturer (as appropriate) for the sole purpose of manufacturing such Intrexon Materials, bulk drug product or bulk quantities of other components of Oragenics Products. The costs
and expenses incurred by Intrexon in carrying out such transfer shall be borne by Intrexon. Any manufacturing Information transferred hereunder to Oragenics or its contract manufacturer shall not be further transferred to any Third Party, including
any Product Sublicensee, or any Oragenics Affiliate without the prior written consent of Intrexon; provided, however, that Intrexon shall not unreasonably withhold such consent if necessary to permit Oragenics to switch manufacturers. 

4.7 Support Services. The study plan produced by Intrexon under Section 1.2(b) and the Work Plan shall describe tasks by which
Intrexon (by itself, through its Affiliates (including Actobiotics), or through designated Third Parties) will provide support services to Oragenics for the research and development of Oragenics Products under the Program, which tasks may be updated
or amended from time to time by the JSC. Oragenics will compensate Intrexon for such support services with cash payments equal to Intrexon’s Fully Loaded Cost in connection with such services. Additionally, from time to time, on an ongoing
basis, Oragenics shall request, or Intrexon may propose, that Intrexon (by itself, through its Affiliates (including Actobiotics), or through designated Third Parties) perform certain additional support services with respect to the Program. To the
extent that the Parties mutually agree that Intrexon (or its Affiliates (including Actobiotics) should perform such additional services, the Parties shall negotiate in good faith the terms under which services would be performed, it being understood
that Intrexon and/or Actobiotics (as appropriate) would be compensated for such services by cash payments equal to their Fully Loaded Cost in connection with such services. 

4.8 Compliance with Law. Each Party shall comply, and shall ensure that its Affiliates, (sub)licensees and Third Party contractors
comply, with all applicable laws, regulations, and guidelines applicable to the Program, including without limitation those relating to the transport, storage, and handling of Intrexon Materials and Oragenics Products. 

4.9 Trademarks and Patent Marking. To the extent permitted by applicable law and regulations, Oragenics shall, and shall ensure that
the packaging, promotional materials, and labeling for Oragenics Products, as appropriate, shall carry, in a conspicuous location, the applicable Intrexon Trademark(s), subject to Oragenics’ reasonable approval of the size, position, and
location thereof. Consistent with the U.S. patent laws, Oragenics shall ensure that 

  
 24 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
Oragenics Products, or their respective packaging or accompanying literature as appropriate, bear applicable and appropriate patent markings for Intrexon Patent numbers. Oragenics shall provide
Intrexon with copies of any materials containing the Intrexon Trademarks or patent markings prior to using or disseminating such materials, in order to obtain Intrexon’s approval thereof. Oragenics’ use of the Intrexon Trademarks and
patent markings shall be subject to prior review and approval of the IPC. Oragenics acknowledges Intrexon’s sole ownership of the Intrexon Trademarks and agrees not to take any action inconsistent with such ownership. Oragenics covenants that
it shall not use any trademark confusingly similar to any Intrexon Trademarks in connection with any products (including any Oragenics Product). From time to time during the Term, Intrexon shall have the right to obtain from Oragenics samples of
Oragenics Product sold by Oragenics or its Affiliates or sublicensees, or other items which reflect public uses of the Intrexon Trademarks or patent markings, for the purpose of inspecting the quality of such Oragenics Products, the use of the
Intrexon Trademarks, or the accuracy of the patent markings. In the event that Intrexon inspects under this Section 4.9, Intrexon shall notify the result of such inspection to Oragenics in writing thereafter. Oragenics shall comply with
reasonable policies provided by Intrexon from time-to-time to maintain the goodwill and value of the Intrexon Trademarks. 
 4.10
Reporting Compliance. During the Term, in the event that Intrexon notifies Oragenics that Intrexon has reasonably concluded, after consultation with its outside advisors, that Intrexon will be required to consolidate Oragenics’ financial
statements with its own or otherwise incorporate summary financial information of Oragenics in one of or more of Intrexon’s financial reports and filings as required by US GAAP or SEC requirements, Oragenics shall comply with the
additional obligations set forth below in this Section 4.10. 
 (a) Oragenics shall keep its books and records consistent with
US GAAP. 
 (b) Oragenics shall provide to Intrexon a complete set of draft basic financial statements and a draft of Oragenics’
Form 10-Q within twenty-eight (28) days after the end of the calendar quarter. Such financial statements may be unaudited and should be prepared in accordance with SEC and US GAAP requirements. Additionally, if not otherwise disclosed in
any such draft Form 10-Q of Oragenics, Oragenics shall provide Intrexon with its anticipated cash dry date concurrent with providing the draft Form 10-Q. 

(c) Oragenics shall provide to Intrexon a complete set of draft audited financial statements, including accompanying footnotes, as of
and for the end of each fiscal year and a draft of Oragenics’ Form 10-K within sixty (60) days after the end of such fiscal year. Such financial statements must be prepared in accordance with SEC and US GAAP requirements.
Additionally, if not otherwise disclosed in any such Form 10-K of Oragenics, Oragenics shall provide Intrexon with its anticipated cash dry date concurrent with providing the draft Form 10-K. 

(d) Oragenics shall communicate in writing as soon as practical to Intrexon any material weaknesses or significant deficiencies in
internal accounting controls as well as context regarding the cause and planned disposition of such material weakness or significant deficiencies. 

  
 25 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (e) Oragenics shall communicate in writing as soon as practical to Intrexon any
adverse event which may result in a material adjustment to the carrying value of Intrexon’s holdings in Oragenics securities. 
 (f)
Oragenics shall provide to Intrexon, within a reasonable time frame, any other items related to Oragenics operations that may be reasonably requested by Intrexon to meet its compliance requirements under applicable laws and regulations,
including filing requirements with the SEC and any other regulators. 
 (g) Oragenics shall work with its external auditors to cause
any necessary auditor consents or other items needed from such external auditors to be provided timely to Intrexon in order for Intrexon to meet any SEC filing requirements or other compliance requirements under applicable laws and regulations. 

4.11 Modification of Deadlines. The parties agree that the delivery deadlines in Section 4.10 will be modified to the extent
necessary to ensure that such deliverables are provided by Oragenics in a reasonable time frame prior to the date necessary for Intrexon to meet any disclosure obligation under rules or regulations to which Intrexon may be or become subject from
time to time. Intrexon will provide Oragenics with notice as promptly as practicable regarding any changes in Intrexon’s disclosure obligations that would require a change in delivery deadlines or cure periods per this Section 4.11. 

4.12 Transfer of Information. Promptly following the Effective Date and in order to support timely adoption of the Work Plan by the
JSC, Intrexon shall promptly provide to Oragenics copies of relevant data, regulatory approvals and regulatory filings that relate to the development and clinical testing of AG013. Thereafter, as additional projects are included in the Program, the
JSC shall develop a plan and protocol for each such project relating to the transfer of relevant data and Intrexon Materials. 
 ARTICLE 5

 COMPENSATION 

5.1 Technology Access Fee. In partial consideration for Oragenics’ appointment as an exclusive channel collaborator in the Field
and the other rights granted to Oragenics hereunder, contemporaneously with the execution of this Agreement Oragenics shall deliver to Intrexon a note in the amount of five million United States dollars ($5,000,000) (the “Technology Access
Fee”) to Intrexon, all in accordance with the terms and conditions of that certain Stock Issuance Agreement of even date herewith (the “Equity Agreement”). Provided that all closing conditions for the full payment of the
fee under this Section 5.1 to Intrexon as set forth in the Equity Agreement that are within the reasonable control of Intrexon have been satisfied or waived, the full payment to Intrexon of the Technology Access Fee (including the final
issuance of any shares by Oragenics as payment therefor per the terms and conditions set forth in the Equity Agreement) is a condition subsequent to the effectiveness of this Agreement. 

  
 26 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 5.2 Milestones. 

(a) Oragenics Commercialization Milestones. Upon the attainment of certain Commercialization Milestone Events by an Oragenics Product
(whether such attainment is achieved by Oragenics or by a permitted sublicensee), Oragenics has agreed to pay Intrexon milestone payments as set forth in this Section 5.2. The milestone payments are each payable, at Oragenics’ election but
subject to Sections 5.2(b) through 5.2(d), either in cash or in shares of Oragenics’ common stock (using Fair Market Value, as defined in the Equity Agreement, to calculate the number of shares to be issued to Intrexon in lieu of cash). The
specific milestone payments due to Intrexon upon achievement of each of the Commercialization Milestone Events are set forth in Sections 5.2(a)(i) through 5.3(a)(vi) below. 

(i) Oragenics shall pay Intrexon a milestone payment of two million United States dollars ($2,000,000) within thirty (30) days of each
achievement of the Phase II Milestone Event for each different Oragenics Product, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or in shares of Oragenics’ common stock. A second
or a subsequent occurrence of the Phase II Milestone Event shall only give rise to an obligation upon Oragenics to make the payment to Intrexon under this Section 5.2(a)(i) if such respective second or subsequent occurrence of the Phase II
Milestone Event occurs after the FDA has granted an approval to an FDA New Product Application for at least one Oragenics Product under the Program. 

(ii) Oragenics shall pay Intrexon a milestone payment of five million United States dollars ($5,000,000) within thirty (30) days of each
achievement of the Phase IIb/III Milestone Event for each different Oragenics Product, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or in shares of Oragenics’ common stock. A
second or a subsequent occurrence of the Phase IIb/III Milestone Event shall only give rise to an obligation upon Oragenics to make the payment to Intrexon under this Section 5.2(a)(ii) if such respective second or subsequent occurrence of the
Phase IIb/III Milestone Event occurs after the FDA has granted an approval to an FDA New Product Application for at least one Oragenics Product under the Program. 

(iii) Oragenics shall pay Intrexon a milestone payment of five million United States dollars ($5,000,000) within thirty (30) days of
each achievement of the Regulatory Approval Application Milestone Event for each different Oragenics Product, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or in shares of
Oragenics’ common stock. A second or a subsequent occurrence of the Regulatory Approval Application Milestone Event shall only give rise to an obligation upon Oragenics to make the payment to Intrexon under this Section 5.2(a)(iii) if such
respective second or subsequent occurrence of the Regulatory Approval Application Milestone Event occurs after the FDA has granted an approval to an FDA New Product Application for at least one Oragenics Product under the Program. 

  
 27 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (iv) Oragenics shall pay Intrexon a milestone payment of ten million United States dollars
($10,000,000) within thirty (30) days of each achievement of the Approval Milestone Event for each different Oragenics Product, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or
in shares of Oragenics’ common stock. 
 (v) Oragenics shall pay Intrexon a one-time milestone payment of five million United States
dollars ($5,000,000) within thirty (30) days of the first instance of the achievement of the New Indication Milestone Event, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or in
shares of Oragenics’ common stock. 
 (vi) Oragenics shall pay Intrexon a one-time milestone payment of five million United States
dollars ($5,000,000) within thirty (30) days of the first instance of the achievement of the New Product Milestone Event, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or in
shares of Oragenics’ common stock. 
 For purposes of subsections (i) through (iv) above in this Section 5.2(a), a later Oragenics
Product shall be deemed to be a “different” Oragenics Product from an earlier Oragenics Product (and thus trigger a subsequent occurrence of the respective milestone payment obligation under any one of subsections (i) through (iv)) if
regulatory approval of the later Oragenics Products must be obtained from the FDA under a different FDA New Product Application than the earlier Oragenics Product. Conversely and for clarity, a later Oragenics Product shall not be deemed
“different” from an earlier Oragenics Product for these milestones if the respective Commercialization Milestone Event occurs in support of a supplemental FDA New Drug Product Application that was being pursued to obtain labeling approval
for new, added, expanded, or amended indications for an earlier Oragenics Product that had already obtained FDA approval (i.e., the respective milestone shall not be triggered a second time in these instances of Oragenics pursuing new indications
for pre-existing and pre-approved Oragenics Products). Notwithstanding anything in this Agreement to the contrary, but subject to its obligation under Section 4.5(a), Oragenics shall have sole and exclusive control over clinical trials
(including patient dosing) and regulatory filings (including the jurisdictions in which such filings are made) for the purpose of the Commercialization Milestones in Section 5.2(a)(i)-(vi) as applicable. 

(b) Milestones After Company Sale or After Reverse Merger. In the event that Oragenics consummates a Company Sale prior to paying to
Intrexon any one or more of the respective milestone payments set forth in Sections 5.2(a)(i) through 5.2(a)(vi) and this Agreement is transferred or assigned to the buyer in connection with such Company Sale, then all subsequent payments for
Commercialization Milestone Events shall thereafter each be 

  
 28 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
payable only in cash to Intrexon. In the event that Oragenics consummates a Reverse Merger, subsequent milestone payments to Intrexon set forth in Sections 5.2(a)(i) through 5.2(a)(vi), shall be
payable, at Intrexon’s option (and not Oragenics’ option), in cash only, in Oragenics common stock only, or in combinations thereof to Intrexon. 

(c) Product Sublicense Milestones. If (A) a Commercialization Milestone Event occurs that gives rise to a right for Intrexon to
receive a payment from Oragenics under Section 5.2(a), (B) that Commercialization Milestone Event is achieved by an Oragenics Product licensed to a Product Sublicensee under a respective Product Sublicense, and (C) Oragenics is due to
receive a milestone payment from the Product Sublicensee for achievement of that same (or substantially similar) Commercialization Milestone Event by the sublicensed Oragenics Product under the respective Product Sublicense, then Intrexon may elect
at its own discretion to waive that particular milestone payment from Oragenics for that particular Commercialization Milestone Event and instead designate the amount of the payment due to Oragenics from the Product Sublicensee for achievement of
that same (or substantially similar) Commercialization Milestone Event as Sublicensing Revenue for which Intrexon will be entitled to receive revenue sharing under Section 5.4(b). If it so elects under this Section 5.2(c), Intrexon must
notify Oragenics in writing of its waiver of the equity-based milestone and election to share the milestone payment due from the Product Sublicensee as Sublicensing Revenue at least five (5) business days prior to the deadline for Oragenics to
make a payment for the waived milestone payment. The actual receipt by Intrexon of its full share of the Product Sublicensee milestone payment as Sublicensing Revenue will be a condition subsequent to making final any waiver of Intrexon’s
rights to receive the particular milestone payment otherwise due from Oragenics under Section 5.2(a). Oragenics will pay Intrexon any amount due under this Section 5.2(c) within the later of (i) thirty (30) days from underlying
Commercialization Milestone Event, or (ii) ten (10) days following the date stipulated in the underlying Product Sublicense for Oragenics to receive the milestone payment. 

(d) Consolidation. The Parties agree that Oragenics’ option to pay any milestone payments that come due for achievement of
Commercialization Milestone Events under this Agreement in equity shall in no event require Intrexon to accept equity of Oragenics as payment if, upon Intrexon’s reasonable conclusion after consultation with its outside advisors, receipt of
such equity payment by Intrexon would cause Intrexon to have to consolidate Oragenics’ financial statements with Intrexon’s financial statements. To this end, upon each achievement of any Commercialization Milestone Event that triggers a
milestone payment being due by Oragenics to Intrexon under Section 5.2(a) above, Oragenics shall notify Intrexon as soon as possible if Oragenics intends to elect to pay the specific milestone payment in equity, such notification being in
writing and delivered to Intrexon in no event less than ten (10) business days from the date of achievement of the respective Commercialization Milestone Event. If Oragenics does not so-notify Intrexon within the time frame set forth in the
prior sentence, such specific Commercialization Milestone payment shall become payable to Intrexon solely in cash. Additionally, upon receiving any notice from Oragenics under the second sentence of this Section 5.2(d) of Oragenics’ intent
to pay a particular Commercialization Milestone payment in equity, Intrexon will therefrom have five (5) business days to consult with its outside advisors to 

  
 29 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
conclude whether the expected payment of Oragenics equity to Intrexon is reasonably likely to cause Intrexon to be required to consolidate Oragenics’ financial statements with its own. If
Intrexon reasonably concludes, after consultation with its outside advisors, that payment of the respective amount in Oragenics equity would cause consolidation, (i) Intrexon may notify Oragenics of this conclusion within such five
(5) business days from Intrexon’s receipt of Oragenics’ notice under this subsection, and (ii) upon Intrexon so-notifying Oragenics, the payment due for achievement of the respective Commercialization Milestone Event shall be
payable by Oragenics solely in cash, provided, however, that in the event Oragenics reasonably concludes that such cash payment would have an adverse effect on its working capital needs over the next twelve (12) months then such cash payment
shall be in the form of an interest bearing (under Section 5.9) promissory note with a maturity date of less than twelve (12) months and including other conventional market terms that would not be expected to unreasonably have an adverse
effect on Oragenics working capital needs over such next twelve (12) months. 
 5.3 Equity Agreement Controls. All issuances of
stock to Intrexon shall be in accordance with the terms and conditions of the Equity Agreement, which Equity Agreement shall control to the extent it may conflict with Sections 5.1 through 5.2 of this Agreement. 

5.4 Revenue Sharing. 

(a) No later than thirty (30) days after each calendar quarter in which there is positive Net Sales arising from the sale of any
Oragenics Product in the Field in the Territory, Oragenics shall pay a royalty to Intrexon of twelve percent (12%) of such Net Sales, on an Oragenics Product-by-Oragenics Product basis. Commencing with the Effective Date, in the event that no
Net Sales occur for a particular Oragenics Product in any calendar quarter, neither Oragenics nor Intrexon shall owe any payments hereunder with respect to such Oragenics Product. 

(b) No later than thirty (30) days after each calendar quarter in which Oragenics or any Oragenics Affiliate receives Sublicensing
Revenue, Oragenics shall pay to Intrexon a percentage of such Sublicensing Revenue equal to the applicable Sublicensing Revenue Rate.  

(c) Intrexon and Actobiotics shall be responsible for determining how any revenue sharing payments from Oragenics due under
Section 5.4(a) and 5.4(b) above are distributed among Intrexon and Actobiotics. 
 5.5 Method of Payment. Except for payments
payable as and made in the form of common stock, payments due to Intrexon under this Agreement shall be paid in United States dollars by wire transfer to a bank (or banks as otherwise set forth in Section 5.8) designated in writing by Intrexon.
All references to “dollars” or “$” herein shall refer to United States dollars. 
 5.6 Payment Reports and Records
Retention. Within thirty (30) days after the end of each calendar quarter during which Net Sales have been generated, during which Sublicensing Revenue has been received, or during which a Commercialization Milestone Event has been achieved
or a payment for such is made or due, Oragenics shall deliver to Intrexon a written report that shall contain at a minimum for the applicable calendar quarter: 

(a) gross sales of each Oragenics Product (on a country-by-country basis); 

  
 30 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (b) itemized calculation of Net Sales, showing all applicable deductions and
calculations; 
 (c) itemized calculation of Sublicensing Revenue, including any offsets claimed for Third Party license costs; 

(d) the amount of the payment (if any) due pursuant to Section 5.4(a) and/or 5.4(b); 

(e) the amount of the payment (if any) made or made due by the achievement of an applicable Commercialization Milestone Event during
the present calendar quarter; 
 (f) the amount of taxes, if any, withheld to comply with any applicable law; and 

(g) the exchange rates used in any of the foregoing calculations. 

For three (3) years after each sale or other commercial use of Oragenics Product, after incurring any component item Oragenics incorporated into its
calculation of Sublicensing Revenues, payments in accord with Section 5.2(b), or Net Sales as reported to Intrexon, Oragenics shall keep (and shall ensure that its Affiliates and, if applicable, (sub)licensees shall keep) complete and accurate
records of such sales, commercial use, or component item in sufficient detail to confirm the accuracy of the payment calculations hereunder. 

5.7 Audits. 
 (a)
Upon the written request of Intrexon, Oragenics shall permit an independent certified public accounting firm of internationally recognized standing selected by Intrexon, and reasonably acceptable to Oragenics, to have access to and to review,
during normal business hours and upon no less than thirty (30) days prior written notice, the applicable records of Oragenics and its Affiliates to verify the accuracy and timeliness of the reports and payments made by Oragenics under this
Agreement. Such review may cover the records for sales made in any calendar year ending not more than three (3) years prior to the date of such request. The accounting firm shall disclose to both Parties whether the royalty reports and/or
know-how reports conform to the provisions of this Agreement and/or US GAAP, as applicable, and the specific details concerning any discrepancies. Such audit may not be conducted more than once in any calendar year. 

(b) If such accounting firm concludes that additional amounts were owed during such period, Oragenics shall pay additional amounts,
with interest from the date originally 

  
 31 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
due as set forth in Section 5.9, within thirty (30) days of receipt of the accounting firm’s written report. If the amount of the underpayment is greater than five percent
(5%) of the total amount actually owed for the period audited, then Oragenics shall in addition reimburse Intrexon for all costs related to such audit; otherwise, Intrexon shall pay all costs of the audit. In the event of overpayment, any
amount of such overpayment shall be fully creditable against amounts payable for the immediately succeeding calendar quarter(s); provided, however, that if such overpayment is reasonably expected to exceed the amount projected to be payable to
Intrexon by Oragenics over next [*****], Intrexon will promptly repay to Oragenics any amount exceeding that projected amount. 

(c) Intrexon shall (i) treat all information that it receives under this Section 5.7 in accordance with the confidentiality
provisions of Article 7 and (ii) cause its accounting firm to enter into an acceptable confidentiality agreement with Oragenics obligating such firm to retain all such financial information in confidence pursuant to such confidentiality
agreement, in each case except to the extent necessary for Intrexon to enforce its rights under this Agreement. 
 5.8 Taxes. The
Parties will cooperate in good faith to obtain the benefit of any relevant tax treaties to minimize as far as reasonably possible any taxes which may be levied on any amounts payable hereunder. Oragenics shall deduct or withhold from any payments
any taxes that it is required by applicable law to deduct or withhold. Notwithstanding the foregoing, if Intrexon is entitled under any applicable tax treaty to a reduction of the rate of, or the elimination of, applicable withholding tax, it may
deliver to Oragenics or the appropriate governmental authority (with the assistance of Oragenics to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of
withholding or to relieve Oragenics of its obligation to withhold tax, and Oragenics shall apply the reduced rate of withholding tax, or dispense with withholding tax, as the case may be, provided that Oragenics has received evidence of
Intrexon’s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least fifteen (15) days prior to the time that the payment is due. If, in accordance with the foregoing, Oragenics
withholds any amount, it shall make timely payment to the proper taxing authority of the withheld amount, and send to Intrexon proof of such payment within forty-five (45) days following that latter payment. Additionally, Intrexon may on an
Oragenics Product-by-Oragenics Product basis, and acting upon reasonable advice of outside tax and/or accounting advisors, request in writing that Oragenics make all of, or a percentage of, any payment that becomes due under Section 5.2 or
Section 5.4 above to Intrexon’s Affiliate directly (instead of to Intrexon), to the extent that such Affiliate has contributed intellectual property to the respective Oragenics Product. To the extent that Oragenics has received such a
request from Intrexon under the prior sentence at least thirty (30) days prior to the time that the payment is due, Oragenics shall honor the request to make the applicable payments (in whole or in part, as applicable) to the Intrexon
Affiliate. 
 5.9 Late Payments. Any amount owed by Oragenics to Intrexon under this Agreement that is not paid within the applicable
time period set forth herein shall accrue interest at the lower of (a) two percent (2%) per month, compounded, or (b) the highest rate permitted under applicable law. 

  
 32 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 ARTICLE 6 

INTELLECTUAL PROPERTY 

6.1 Ownership. 
 (a)
Subject to the license granted under Section 3.1, all rights in the Intrexon IP shall remain with Intrexon. 
 (b) Oragenics
and/or Intrexon may solely or jointly conceive, reduce to practice or develop discoveries, inventions, processes, techniques, and other technology, whether or not patentable, in the course of performing the Program (collectively
“Inventions”). Each Party shall promptly provide the other Party with a detailed written description of any such Inventions that relate to the Field. Inventorship shall be determined in accordance with United States patent laws.

 (c) Intrexon shall solely own all right, title and interest in all Inventions related to Intrexon Channel Technology, together
with all Patent rights and other intellectual property rights therein (the “Channel-Related Program IP”). Oragenics hereby assigns all of its right, title and interest in and to the Channel-Related Program IP to Intrexon. Oragenics
agrees to execute such documents and perform such other acts as Intrexon may reasonably request to obtain, perfect and enforce its rights to the Channel-Related Program IP and the assignment thereof. 

(d) Notwithstanding anything to the contrary in this Agreement, any discovery, invention, process, technique, or other technology,
whether or not patentable, that is conceived, reduced to practice or developed by Oragenics solely or jointly through the use of the Intrexon Channel Technology, Intrexon IP, or Intrexon Materials in breach of the terms and conditions of this
Agreement, together with all patent rights and other intellectual property rights therein, shall be solely owned by Intrexon and shall be included in the Channel-Related Program IP. 

(e) All Information regarding Channel-Related Program IP shall be Confidential Information of Intrexon. Oragenics shall be under
appropriate written agreements with each of its employees, contractors, or agents working on the Program, pursuant to which such person shall grant all rights in the Inventions to Oragenics (so that Oragenics may convey certain of such rights to
Intrexon, as provided herein) and agree to protect all Confidential Information relating to the Program. 
 (f) All rights,
technology, and intellectual property (A) owned by Oragenics or licensed from a Third Party by Oragenics as of the Effective Date, or (B) thereafter developed by Oragenics independent of the Program, Actobiotics IP, Intrexon Channel
Technology, Intrexon IP or Intrexon Materials, shall be owned by and remain the property of Oragenics (the “Oragenics Independent IP”). 

  
 33 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 6.2 Patent Prosecution. 

(a) Intrexon shall have the sole right, but not the obligation, to (a) conduct and control the filing, prosecution and maintenance
of the Intrexon Patents, and (b) conduct and control the filing, prosecution, and maintenance of any applications for patent term extension and/or supplementary protection certificates for the Intrexon Patents that may be available as a result
of the regulatory approval of any Oragenics Product. At the reasonable request of Intrexon, Oragenics shall cooperate with Intrexon in connection with such filing, prosecution, and maintenance, at Intrexon’s expense. Under no circumstances
shall Oragenics (a) file, attempt to file, or assist anyone else in filing, or attempting to file, any Patent application, either in the United States or elsewhere, that claims or uses or purports to claim or use or relies for support upon an
Invention owned by Intrexon, (b) use, attempt to use, or assist anyone else in using or attempting to use, the Intrexon Know-How, Intrexon Materials, or any Confidential Information of Intrexon to support the filing of a Patent application,
either in the United States or elsewhere, that contains claims directed to the Intrexon IP, Intrexon Materials, or the Intrexon Channel Technology, or (c) without prior approval of the IPC, file, attempt to file, or assist anyone else in
filing, or attempting to file, any application for patent term extension or supplementary protection certificate, either in the United States or elsewhere, that relies upon the regulatory approval of an Oragenics Product. 

(b) Oragenics shall have the sole right, but not the obligation, to conduct and control the filing, prosecution and maintenance of any
Patents claiming Inventions that are owned by Oragenics or its Affiliates and not assigned to Intrexon under Section 6.1(c) (“Oragenics Program Patents”). At the reasonable request of Oragenics, Intrexon shall cooperate with
Oragenics in connection with such filing, prosecution, and maintenance, at Oragenics’ expense. 
 (c) As used herein,
“Prosecuting Party” means Intrexon in the case of Intrexon Patents and Oragenics in the case of Oragenics Program Patents. The Prosecuting Party shall be entitled to use patent counsel selected by it and reasonably acceptable to the
non-Prosecuting Party (including in-house patent counsel as well as outside patent counsel) for the prosecution of the Intrexon Patents and Oragenics Program Patents, as applicable. The Prosecuting Party shall: 

(i) regularly provide the other Party in advance with reasonable information relating to the Prosecuting Party’s prosecution of Patents
hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and copies of drafts of filings and correspondence that the Prosecuting Party proposes to
submit to such patent authorities (it being understood that, to the extent that any such information is readily accessible to the public, the Prosecuting Party may, in lieu of directly providing copies of such information to such other Party,
provide such other Party with sufficient information that will permit such other Party to access such information itself directly); 

  
 34 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (ii) consider in good faith and consult with the non-Prosecuting Party regarding its timely
comments with respect to the same; provided, however, that if, within fifteen (15) days after providing any documents to the non-Prosecuting Party for comment, the Prosecuting Party does not receive any written communication from the
non-Prosecuting Party indicating that it has or may have comments on such document, the Prosecuting Party shall be entitled to assume that the non-Prosecuting Party has no comments thereon; 

(iii) consult with the non-Prosecuting Party before taking any action that would reasonably be expected to have a material adverse impact on
the scope of claims within the Intrexon Patents and Oragenics Program Patents, as applicable. 
 6.3 Infringement of Patents by Third
Parties. 
 (a) Except as expressly provided in the remainder of this Section 6.3, Intrexon shall have the sole right to
take appropriate action against any person or entity directly or indirectly infringing any Intrexon Patent (or asserting that an Intrexon Patent is invalid or unenforceable) (collectively, “Infringement”), either by settlement or
lawsuit or other appropriate action. 
 (b) Notwithstanding the foregoing, Oragenics shall have the first right, but not the
obligation, to take appropriate action to enforce Product-Specific Program Patents against any Infringement that involves a commercially material amount of allegedly infringing activities in the Field (“Field Infringement”), either
by settlement or lawsuit or other appropriate action. If Oragenics exercises the foregoing right, Intrexon agrees to be named in any such action if required. If Oragenics fails to take the appropriate steps to enforce Product-Specific Program
Patents against any Field Infringement within one hundred eighty (180) days of the date one Party has provided notice to the other Party pursuant to Section 6.3(g) of such Field Infringement, then Intrexon shall have the right (but not the
obligation), at its own expense, to enforce Product-Specific Program Patents against such Field Infringement, either by settlement or lawsuit or other appropriate action. 

(c) With respect to any Field Infringement that cannot reasonably be abated through the enforcement of Product-Specific Program Patents
pursuant to Section 6.3(b) but can reasonably be abated through the enforcement of Intrexon Patent(s) (other than the Product-Specific Program Patents), Intrexon shall be obligated to choose one of the following courses of action:
(i) enforce one or more of the applicable Intrexon Patent(s) in a commercially reasonable manner against such Field Infringement, or (ii) [*****]. The Party enforcing the applicable Intrexon Patent(s) shall bear the costs and
expenses of such enforcement. The determination of which Intrexon Patent(s) to assert shall be made by Intrexon in its sole discretion; provided, however, that Intrexon shall consult in good faith with Oragenics on such determination. For the
avoidance of doubt, Intrexon has no obligations under this Agreement to enforce any Intrexon Patents against, or otherwise abate, any Infringement that is not a Field Infringement. 

  
 35 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (d) In the event a Party pursues an action under this Section 6.3, the other
Party shall reasonably cooperate with the enforcing Party with respect to the investigation and prosecution of any alleged, threatened, or actual Infringement, at the enforcing Party’s expense. 

(e) Oragenics shall not settle or otherwise compromise any action under this Section 6.3 in a way that diminishes the rights or
interests of Intrexon outside the Field or adversely affects any Intrexon Patent without Intrexon’s prior written consent, which consent shall not be unreasonably withheld. Intrexon shall not settle or otherwise compromise any action under this
Section 6.3 in a way that diminishes the rights or interests of Oragenics in the Field or adversely affects any Intrexon Patent with respect to the Field without Oragenics’ prior written consent, which consent shall not be unreasonably
withheld. 
 (f) Except as otherwise agreed to by the Parties in writing, any settlements, damages or other monetary awards recovered
pursuant to a suit, proceeding, or action brought pursuant to Section 6.3 will be allocated first to the costs and expenses of the Party controlling such action, and second, to the costs and expenses (if any) of the other Party (to the extent
not otherwise reimbursed), and any remaining amounts (the “Recovery”) will be shared by the Parties as follows: In any action initiated by Intrexon pursuant to Section 6.3(a) that does not involve Field Infringement, or in any
action initiated by Intrexon pursuant to Section 6.3(b), Intrexon shall retain one hundred percent (100%) of any Recovery. In any action initiated by Oragenics pursuant to Section 6.3(b), [*****]. In any action initiated by
Intrexon or Oragenics pursuant to Section 6.3(c), the enforcing Party shall retain one hundred percent (100%) of any Recovery. 

(g) Oragenics shall promptly notify Intrexon in writing of any suspected, alleged, threatened, or actual Infringement of which it
becomes aware, and Intrexon shall promptly notify Oragenics in writing of any suspected, alleged, threatened, or actual Field Infringement of which it becomes aware. 

ARTICLE 7 

CONFIDENTIALITY 

7.1 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each
Party agrees that it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement any Confidential Information disclosed to it by the other Party pursuant to this
Agreement, except to the extent that the receiving Party can demonstrate by competent evidence that specific Confidential Information: 

(a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other
Party; 
 (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the
receiving Party; 

  
 36 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (c) became generally available to the public or otherwise part of the public domain
after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
 (d) was
disclosed to the receiving Party, other than under an obligation of confidentiality to a Third Party, by a Third Party who had no obligation to the disclosing Party not to disclose such information to others; or 

(e) was independently discovered or developed by the receiving Party without the use of Confidential Information belonging to the
disclosing Party, as documented by the receiving Party’s written records. 
 The foregoing non-use and non-disclosure obligation shall
continue (i) indefinitely, for all Confidential Information that qualifies as a trade secret under applicable law; or (ii) for the Term of this Agreement and for seven (7) years thereafter, in all other cases. 

7.2 Authorized Disclosure. Notwithstanding the limitations in this Article 7, either Party may disclose the Confidential Information
belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances: 
 (a) complying with
applicable laws or regulations or valid court orders, provided that the Party making such disclosure provides the other Party with reasonable prior written notice of such request or demand for disclosure and makes a reasonable effort to
obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the disclosure and/or requiring that the terms and conditions of this Agreement be used only for the purposes for which the law or regulation required, or
for which the order was issued; 
 (b) to regulatory authorities in order to seek or obtain approval to conduct clinical trials, or
to gain regulatory approval, of Oragenics Products or any products being developed by Intrexon or its other licensees and/or channel partners or collaborators, provided that the Party making such disclosure (i) provides the other Party with
reasonable opportunity to review any such disclosure in advance and to suggest redactions or other means of limiting the disclosure of such other Party’s Confidential Information and (ii) does not unreasonably reject any such suggestions;

 (c) disclosure to investors and potential investors, acquirers, or merger candidates who agree to maintain the confidentiality of
such information, provided that such disclosure is used solely for the purpose of evaluating such investment, acquisition, or merger (as the case may be); 

(d) disclosure on a need-to-know basis to Affiliates, licensees, sublicensees, employees, consultants or agents (such as CROs and
clinical investigators) who agree to be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7; and 

(e) disclosure of the terms of this Agreement by Intrexon to collaborators and other channel partners or collaborators who agree to be
bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7. 

  
 37 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 7.3 Publicity; Publications. The Parties agree that the public announcement of the
execution of this Agreement shall be substantially in the form of a press release (the form of which shall be mutually agreed to by the Parties) and/or the filing of a Form 8-K by one or both of the Parties (to the extent required by relevant laws
or regulations relating to required disclosure of material information to public markets and/or the SEC). Each Party will provide the other Party with the opportunity to review and comment, prior to submission or presentation, on external reports,
securities filings, publications and presentations (e.g., press releases, reports to government agencies, abstracts, posters, manuscripts and oral presentations) that refer to the Program, Oragenics Products, or programs that are approved by the
JSC. For such reports, publications, and presentations, the disclosing Party will provide the other Party at least fifteen (15) calendar days for review of the proposed submission or presentation. In the case of a Form 8-K filing, such shall be
provided to the non-filing Party by the filing party as soon as practicable prior to filing for review and comment. For reports and manuscripts, the disclosing Party will provide the other Party at least thirty (30) days for review of the
report or manuscript. The presenting Party will act in good faith to incorporate the comments of the other Party and shall, in any event, redact any Confidential Information of the other Party and cooperate with the other Party to postpone such
submissions or presentations if necessary to provide the other Party with sufficient time to prepare and file any related Patent applications before the submission or presentation occurs, as appropriate. 

7.4 Terms of the Agreement. Each Party shall treat the terms of this Agreement as the Confidential Information of other Party, subject
to the exceptions set forth in Section 7.2. Notwithstanding the foregoing, each Party acknowledges that the other Party may be obligated to file a copy of this Agreement with the SEC, either as of the Effective Date or at some point during the
Term. Each Party shall be entitled to make such a required filing, provided that it requests confidential treatment of certain commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably available to
it. In the event of any such filing, the filing Party shall provide the other Party with a copy of the Agreement marked to show provisions for which the filing Party intends to seek confidential treatment and shall reasonably consider and
incorporate the other Party’s comments thereon to the extent consistent with the legal requirements governing redaction of information from material agreements that must be publicly filed. The other Party shall promptly provide any such
comments. 
 7.5 Proprietary Information and Operational Audits. 

(a) For the purpose of confirming compliance with the Field-limited licenses granted in Article 3, the diligence obligations of Article
4, and the confidentiality obligations under Article 7, Oragenics acknowledges that Intrexon’s authorized representative(s), during regular business hours may (i) examine and inspect Oragenics’ facilities and (ii) inspect all
data and work products relating to this Agreement, subject to restrictions imposed by applicable laws. 

  
 38 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
Any examination or inspection hereunder shall require five (5) business days written notice from Intrexon to Oragenics. Oragenics will make itself and the pertinent employees and/or agents
available, on a reasonable basis, to Intrexon for the aforementioned compliance review. 
 (b) For the purpose of confirming
compliance with the diligence obligations of Section 4.6, and the confidentiality obligations under Article 7, Intrexon acknowledges that Oragenics authorized representative(s), during regular business hours may (i) examine and inspect
Intrexon’s facilities and (ii) inspect all data and work products relating to this Agreement. Any examination or inspection hereunder shall require five (5) business days written notice from Oragenics to Intrexon. Intrexon will make
itself and the pertinent employees and/or agents available, on a reasonable basis, to Oragenics for the aforementioned compliance review. 

(c) In view of the Intrexon Confidential Information, Intrexon Know-How, and Intrexon Materials transferred to Oragenics hereunder,
Intrexon from time-to-time, but no more than quarterly, may request that Oragenics confirm the status of the Intrexon Materials at Company (i.e. how much used, how much shipped, to whom and any unused amounts destroyed (by whom, when) as well as any
amounts returned to Intrexon or destroyed). Within ten (10) business days of Oragenics’ receipt of any such written request, Oragenics shall provide the written report to Intrexon. 

7.6 Intrexon and Actobiotics Commitment. Intrexon and Actobiotics shall use reasonable efforts to obtain an agreement with its other
licensees and channel partners or collaborators to enable Oragenics to disclose confidential information of such licensees and channel partners or collaborators to regulatory authorities in order to seek or obtain approval to conduct clinical
trials, or to gain regulatory approval of, Oragenics Products, in a manner consistent with the provisions of Section 7.2(b). 

ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

8.1 Representations and Warranties of Oragenics. Oragenics hereby represents and warrants to Intrexon and Actobiotics that, as of the
Effective Date: 
 (a) Corporate Power. Oragenics is duly organized and validly existing under the laws of Florida and has corporate
full power and authority to enter into this Agreement and to carry out the provisions hereof. 
 (b) Due Authorization. Oragenics is
duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on Oragenics’ behalf has been duly authorized to do so by all requisite corporate action. 

(c) Binding Agreement. This Agreement is a legal and valid obligation binding upon Oragenics and enforceable in accordance with its
terms, except as such 

  
 39 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights, and subject to general equity
principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Oragenics does not conflict with any agreement, instrument or understanding, oral or
written, to which it is a party or by which it may be bound. Oragenics is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement. 

8.2 Representations and Warranties of Intrexon and Actobiotics. Intrexon and Actobiotics hereby represent and warrant to Oragenics
that, as of the Effective Date: 
 (a) Corporate Power. Intrexon and Actobiotics are duly organized and validly existing under the
laws of the jurisdiction of its organization and have full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 

(b) Due Authorization. Intrexon and Actobiotics are duly authorized to execute and deliver this Agreement and to perform its
obligations hereunder, and the person executing this Agreement on Intrexon’s and Actobiotics’s behalf has been duly authorized to do so by all requisite corporate action. 

(c) Binding Agreement. This Agreement is a legal and valid obligation binding upon Intrexon and Actobiotics and enforceable in
accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights, and subject to general equity principles and
to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Intrexon and Actobiotics does not conflict with any agreement, instrument or understanding, oral or
written, to which it is a party or by which it may be bound. Intrexon is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement. 

(d) Additional Intellectual Property Representations. 

(i) Intrexon and Actobiotics possesses sufficient rights to enable them to grant all rights and licenses it purports to grant to Oragenics
with respect to the Intrexon IP and Actobiotics IP under this Agreement; 
 (ii) The Intrexon IP and the Actobiotics IP existing as of the
Effective Date constitute all of the intellectual property Controlled by Intrexon and Actobiotics as of such date that is necessary for the development, manufacture or Commercialization of Oragenics Products; 

(iii) Intrexon and Actobiotics have not granted, and during the Term Intrexon and Actobiotics will not grant, any right or license, to any
Third Party under the Intrexon IP and Actobiotics IP that conflicts with the rights or licenses granted or to be granted to Oragenics hereunder 

  
 40 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (iv) There is no pending litigation, and neither Intrexon nor Actobiotics has received any
written notice of any claims or litigation, seeking to invalidate or otherwise challenge the Intrexon IP or Intrexon’s rights therein or the Actobiotics IP or Actobiotics’s rights therein; 

(v) None of the Intrexon IP or Actobiotics IP is subject to any pending re-examination, opposition, interference or litigation proceedings;

 (vi) All of the Intrexon Patents and Actobiotics Patents have been filed and prosecuted in accordance with all applicable laws and have
been maintained, with all applicable fees with respect thereto (to the extent such fees have come due) having been paid; 
 (vii) Intrexon
and Actobiotics have entered into agreements with each of its current and former officers, employees and consultants involved in research and development work, including development of the Intrexon’s and Actobiotics’s products and
technology providing Intrexon and Actobiotics, to the extent permitted by law, with title and ownership to patents, patent applications, trade secrets and inventions conceived, developed, reduced to practice by such person, solely or jointly with
other of such persons, during the period of employment by or contract with Intrexon or Actobiotics (except where the failure to have entered into such an agreement would not have a material adverse effect on the rights granted to Oragenics herein),
and neither Intrexon nor Actobiotics is aware that any of its employees or consultants is in material violation thereof; 
 (viii) To
Intrexon’s and/or Actobiotics’s knowledge, there is no infringement, misappropriation or violation by Third Parties of any Intrexon Channel Technology, Intrexon IP, or Actobiotics IP in the Field; 

(ix) There is no pending or, to Intrexon’s and/or Actobiotics’s knowledge, threatened action, suit, proceeding or claim by others
against Intrexon that Intrexon infringes, misappropriates or otherwise violates any intellectual property or other proprietary rights of others in connection with the use of the Intrexon Channel Technology, Intrexon IP, and Actobiotics IP, and
neither Intrexon nor Actobiotics has received any written notice of such claim; 
 (x) To Intrexon’s and/or Actobiotics’s
knowledge, no employee of Intrexon or Actobiotics is the subject of any claim or proceeding involving a violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement,
non-solicitation agreement, non-disclosure agreement or any restrictive covenant to or with a former employer (A) where the basis of such violation relates to such employee’s employment with Intrexon or Actobiotics or actions undertaken by
the employee while employed with Intrexon or Actobiotics and (B) where such violation is relevant to the use of the Intrexon Channel Technology or Actobiotics IP in the Field; 

  
 41 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (xi) None of the Patents in the Actobiotics IP or Intrexon IP, and, to Intrexon’s
and/or Actobiotics’s knowledge, none of the Patents licensed in the Actobiotics IP or Intrexon IP to Intrexon or its Affiliates, have been adjudged invalid or unenforceable by a court of competent jurisdiction or applicable government agency,
in whole or in part, and there is no pending or, to Intrexon’s and/or Actobiotics’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intrexon Patents; and 

(xii) Except as otherwise disclosed in writing to Oragenics, Intrexon and Actobiotics: (A) are in material compliance with all statutes,
rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product that is under
development, manufactured or distributed by Intrexon and Actobiotics in the Field (“Applicable Laws”); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or
notice from the United States Food and Drug Administration (the “FDA”) or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any Applicable Laws or any
licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), which would, individually or in the aggregate, result in a
material adverse effect; (C) possesses all material Authorizations necessary for the operation of its business as described in the Field and such Authorizations are valid and in full force and effect and Intrexon is not in material violation of
any term of any such Authorizations; and (D) since January 1, 2011, (1) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other
federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any other
federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit investigation or proceeding; (2) has not received notice that the FDA or any other
federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any other federal, state, local
or foreign governmental or regulatory authority is considering such action; (3) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or
amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or
were corrected or supplemented by a subsequent submission); and (4) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement,
safety alert, post-sale warning, “dear doctor” letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to Intrexon’s knowledge, no third party
has initiated, conducted or intends to initiate any such notice or action 
 (xiii) Prior to the Effective Date, Intrexon and Actobiotics
have provided Oragenics with copies of all material correspondence, communications, and filings with the FDA and other regulatory authorities regarding AG013 and its pre-clinical and clinical testing, and associated underlying reports and data. 


  
 42 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 except, in each of (ix) through (xiii), for any instances which would not, individually or in the
aggregate, result in a material adverse effect on the rights granted to Oragenics hereunder or Intrexon’s or Actobiotics’s ability to perform its obligations hereunder. 

8.3 Warranty Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES PROVIDED IN THIS ARTICLE 8 OR IN THE EQUITY AGREEMENT, EACH PARTY HEREBY
DISCLAIMS ANY AND ALL OTHER WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

ARTICLE 9 

INDEMNIFICATION 

9.1 Indemnification by Intrexon. Intrexon agrees to indemnify, hold harmless, and defend Oragenics and its Affiliates and their
respective directors, officers, employees, and agents (collectively, the “Oragenics Indemnitees”) from and against any and all liabilities, damages, costs, expenses, or losses (including reasonable legal expenses and attorneys’
fees) (collectively, “Losses”) resulting from any claims, suits, actions, demands, or other proceedings brought by a Third Party (collectively, “Claims”) to the extent arising from (a) the negligence or willful
misconduct of Intrexon or any of its Affiliates, or their respective employees or agents, (b) the use, handling, storage or transport of Intrexon Materials or materials that are Actobiotics IP, by Intrexon or its Affiliates, licensees (other
than Oragenics) or sublicensees; or (c) breach by Intrexon or Actobiotics of any representation, warranty or covenant in this Agreement. Notwithstanding the foregoing, Intrexon shall not have any obligation to indemnify the Oragenics
Indemnitees to the extent that a Claim arises from (i) the negligence or willful misconduct of Oragenics or any of its Affiliates, licensees, or sublicensees, or their respective employees or agents; or (ii) a breach by Oragenics of a
representation, warranty, or covenant of this Agreement. 
 9.2 Indemnification by Oragenics. Oragenics agrees to indemnify, hold
harmless, and defend Intrexon, its Affiliates and Third Security, and their respective directors, officers, employees, and agents (and any Third Parties which have licensed to Intrexon intellectual property rights within Intrexon IP on or prior to
the Effective Date, to the extent required by the relevant upstream license agreement) (collectively, the “Intrexon Indemnitees”) from and against any Losses resulting from Claims, to the extent arising from any of the following:
(a) the negligence or willful misconduct of Oragenics or any of its Affiliates or their respective 

  
 43 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
employees or agents; (b) the use, handling, storage, or transport of Intrexon Materials or materials that are Actobiotics IP by Oragenics or its Affiliates, licensees, or sublicensees;
(c) breach by Oragenics of any material representation, warranty or covenant in this Agreement; or (d) the design, development, manufacture, regulatory approval, handling, storage, transport, distribution, sale or other disposition of any
Oragenics Product by Oragenics or its Affiliates, licensees, or sublicensees. Notwithstanding the foregoing, Oragenics shall not have any obligation to indemnify the Intrexon Indemnitees to the extent that a Claim arises from (i) the negligence
or willful misconduct of Intrexon or any of its Affiliates, or their respective employees or agents; or (ii) a breach by Intrexon of a representation, warranty, or covenant of this Agreement. 

9.3 Product Liability Claims. Notwithstanding the provisions of Section 9.2, any Losses arising out of any Third Party claim,
suit, action, proceeding, liability or obligation involving any actual or alleged death or bodily injury arising out of or resulting from the development, manufacture or Commercialization of any Oragenics Products for use or sale in the Field, to
the extent that such Losses exceed the amount (if any) covered by the applicable Party’s product liability insurance (“Excess Product Liability Costs”), shall be paid by [*****], except to the extent such Losses arise
out of any Third-Party Claim based on the gross negligence or willful misconduct of a Party, its Affiliates, or its Affiliates’ sublicensees, or any of the respective officers, directors, employees and agents of each of the foregoing entities,
in the performance of obligations or exercise of rights under this Agreement. 
 9.4 Control of Defense. As a condition precedent to
any indemnification obligations hereunder, any entity entitled to indemnification under this Article 9 shall give written notice to the indemnifying Party of any Claims that may be subject to indemnification, promptly after learning of such Claim.
If such Claim falls within the scope of the indemnification obligations of this Article 9, then the indemnifying Party shall assume the defense of such Claim with counsel reasonably satisfactory to the indemnified Party. The indemnified Party shall
cooperate with the indemnifying Party in such defense. The indemnified Party may, at its option and expense, be represented by counsel of its choice in any action or proceeding with respect to such Claim. The indemnifying Party shall not be liable
for any litigation costs or expenses incurred by the indemnified Party without the indemnifying Party’s written consent, such consent not to be unreasonably withheld. The indemnifying Party shall not settle any such Claim if such settlement
(a) does not fully and unconditionally release the indemnified Party from all liability relating thereto or (b) adversely impacts the exercise of the rights granted to the indemnified Party under this Agreement, unless the indemnified
Party otherwise agrees in writing. 
 9.5 Insurance. Immediately prior to, and during marketing of Oragenics Products, Oragenics
shall maintain, and shall cause its permitted sublicensees to maintain, in effect and good standing a product liability insurance policy issued by a reputable insurance company in amounts considered standard for the industry. Immediately prior to,
and during the conduct of any clinical trials, Oragenics shall maintain, and shall cause any relevant permitted sublicensees to maintain, in effect and good standing a clinical trials liability insurance policy issued by a


  
 44 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
reputable insurance company in amounts considered standard for the industry. At Intrexon’s reasonable request, Oragenics shall provide Intrexon with all details regarding such policies,
including without limitation copies of the applicable liability insurance contracts. Oragenics shall use reasonable efforts to include Intrexon as an additional insured on any such policies. 

ARTICLE 10 

TERM; TERMINATION 

10.1 Term. The term of this Agreement shall commence upon the Effective Date and shall continue until terminated pursuant to
Section 10.2 or 10.3 (the “Term”). 
 10.2 Termination for Material Breach; Termination Under Section 4.5(b)

 (a) Either Party shall have the right to terminate this Agreement upon written notice to the other Party if the other Party
commits any material breach of this Agreement that such breaching Party fails to cure within sixty (60) days following written notice from the non-breaching Party specifying such breach, provided, however, that solely for purposes of
Section 9.5 the cure period shall be ninety (90) days. 
 (b) Intrexon shall have the right to terminate this Agreement, at
its sole discretion, if the Technology Access Fee has not been paid in accordance with the terms and conditions of this Agreement and the Equity Agreement, including if the full principal on the Note (as defined in the Equity Agreement) has not been
paid within the timeframes set forth in the Note (including the issuance to Intrexon of any shares in payment thereof). 
 (c)
Intrexon shall have the right to terminate this Agreement under the circumstances set forth in Section 4.5(b) upon written notice to Oragenics, such termination to become effective sixty (60) days following such written notice unless
Oragenics remedies the circumstances giving rise to such termination within such sixty (60) day period. 
 (d) Intrexon shall
have the right to terminate this Agreement should Oragenics execute any purported assignment of this Agreement contrary to the prohibitions in Section 12.8, such termination occurring upon Intrexon providing written notice to Oragenics and
becoming effective immediately upon such written notice. 
 (e) Intrexon hereby acknowledges that Oragenics will need to raise
additional capital in order to carry out its obligations under this Agreement and during the sixteen (16) month period commencing on the Effective Date (the “Initial Financing Period”) Intrexon shall not have the right during
the Initial Financing Period (i) to terminate this Agreement under Section 10.2(a) based on the failure of a Party to use Diligent Efforts or to comply with any other diligence obligations hereunder (including Section 4.5), or
(ii) to terminate this Agreement under Section 10.2(c). Notwithstanding the foregoing, (i) the Parties shall pursue the Initial Study in accord with the terms and conditions of this Agreement with Diligent Efforts during the Initial
Financing Period, and (ii) the Parties, for clarity, shall only be absolved of failing to advance the  

  
 45 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
Program (other than the Initial Study) with Diligent Efforts during the Initial Financing Period to the extent that any such failure to use Diligent Efforts is due to Oragenics working
capital and financing considerations. Additionally, Intrexon agrees to reasonably cooperate to assist Oragenics in its undertaking to seek financing during the Initial Financing Period, and agrees to participate in any financing to the extent
necessary for Oragenics to obtain financing necessary to support research and development activities for collaborative Intrexon and Oragenics programs during the Initial Financing Period (including for the Initial Study) [*****].
Notwithstanding the foregoing, Intrexon’s agreement to participate in financing under the prior sentence shall not obligate Intrexon to participate in any such financing to the extent that such financing occurs or closes after a Reverse Merger.
 
 10.3 Termination by Oragenics. Following the full payment of the Technology Access Fee to Intrexon in full satisfaction of
the terms of the Equity Agreement, Oragenics shall have the right to voluntarily terminate this Agreement in its entirety upon ninety (90) days written notice to Intrexon. 

10.4 Effect of Termination. In the event of termination of this Agreement pursuant to Section 10.2 or Section 10.3, the
following shall apply: 
 (a) Retained Products. Oragenics shall be permitted to continue the clinical development and
Commercialization in the Field of any product resulting from the Program that, at the time of any termination, satisfies at least one of the following criteria (a “Retained Product”): 

(i) the particular product is an Oragenics Product that is being sold by Oragenics (or, as may be permitted in accord with this Agreement,
its Affiliates or sublicensees) triggering profit sharing payments therefor under Sections 5.4(a) or 5.4(b) of this Agreement, 
 (ii) the
particular product is an Oragenics Product has received regulatory approval, 
 (iii) the particular product is an Oragenics Product that
is the subject of an application for regulatory approval in the Field that is pending before the applicable regulatory authority, 
 (iv)
the particular product is the specific Oragenics Product AG013, and such Oragenics Product has been the subject of at least one completed phase II clinical trial (as such is defined by relevant FDA guidelines) during the Term, or 

(v) the particular product is an Oragenics Product other than AG013, and such Oragenics Product is the subject of at least an ongoing phase
I, phase II or phase III clinical trial in the Field (in the case of a termination by Intrexon due to an Oragenics uncured breach pursuant to Section 10.2(a) or a termination by Oragenics pursuant to Section 10.3). 

  
 46 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 Such rights to continue development and Commercialization under this Section 10.4(a) shall be subject to
Oragenics’ full compliance with the payment provisions in Article 5, a continuing obligation for Oragenics to use in accord with Sections 4.5(a) and 4.5(c) Diligent Efforts to develop and Commercialize any Retained Products, and all other
provisions of this Agreement that survive termination. 
 (b) Termination of Licenses. Except as necessary for Oragenics to continue
to obtain regulatory approval for, clinically develop, use, manufacture and Commercialize the Retained Products in the Field as permitted by Section 10.4(a), all rights and licenses granted by Intrexon to Oragenics under this Agreement shall
terminate and shall revert to Intrexon without further action by either Intrexon or Oragenics. Oragenics’ license with respect to Retained Products shall be exclusive or non-exclusive, as the case may be, on the same terms as set forth in
Section 3.1. 
 (c) Reverted Products. All Oragenics Products other than the Retained Products shall be referred to herein as
the “Reverted Products.” Oragenics shall immediately cease, and shall cause its Affiliates and, if applicable, (sub)licensees to immediately cease, all development and Commercialization of the Reverted Products, and Oragenics shall
not use or practice, nor shall it cause or permit any of its Affiliates or, if applicable, (sub)licensees to use or practice, directly or indirectly, any Intrexon IP with respect to the Reverted Products. Oragenics shall immediately discontinue
making any representation regarding its status as a licensee or channel collaborator of Intrexon with respect to the Reverted Products. 

(d) Intrexon Materials. Oragenics shall promptly return, or at Intrexon’s request, destroy, any Intrexon Materials in
Oragenics’ possession or control at the time of termination other than any Intrexon Materials necessary for the continued development, regulatory approval, use, manufacture and Commercialization of the Retained Products in the Field. 

(e) Licenses to Intrexon. Oragenics is automatically deemed to grant to Intrexon a worldwide, fully paid, royalty-free, exclusive (even
as to Oragenics and its Affiliates), irrevocable, license (with full rights to sublicense) under the Oragenics Termination IP, to make, have made, import, use, offer for sale and sell Reverted Products and to use the Intrexon Channel Technology, the
Intrexon Materials, and/or the Intrexon IP in the Field, subject to any exclusive rights held by Oragenics in Reverted Products pursuant to Section 10.4(c). The Parties shall also take such actions and execute such other instruments and
documents as may be reasonably necessary to document such license to Intrexon. 
 (f) Regulatory Filings. Oragenics shall promptly
assign to Intrexon, and will provide full copies of, all regulatory approvals and regulatory filings that relate specifically and solely to Reverted Products. Oragenics shall also take such actions and execute such other instruments, assignments and
documents as may be necessary to effect the transfer of rights thereunder to Intrexon. To the extent that there exist any regulatory approvals and regulatory filings that relate both to Reverted Products and other products, Oragenics shall provide
copies 

  
 47 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
of the portions of such regulatory filings that relate to Reverted Products and shall reasonably cooperate to assist Intrexon in obtaining the benefits of such regulatory approvals with respect
to the Reverted Products. 
 (g) Data Disclosure. Oragenics shall provide to Intrexon copies of the relevant portions of all material
reports and data, including clinical and non-clinical data and reports, obtained or generated by or on behalf of Oragenics or its Affiliates to the extent that they relate to Reverted Products, within sixty (60) days of such termination unless
otherwise agreed, and Intrexon shall have the right to use any such Information in developing and Commercializing Reverted Products and to license any Third Parties to do so. 

(h) Third-Party Licenses. At Intrexon’s request, Oragenics shall promptly provide to Intrexon copies of all Third-Party agreements
under which Oragenics or its Affiliates obtained a license under Patents claiming inventions or know-how specific to or used or incorporated into the development, manufacture and/or Commercialization of the Reverted Products. At Intrexon’s
request such that Intrexon may Commercialize the Reverted Products, Oragenics shall promptly work with Intrexon to either, as appropriate, (A) assign to Intrexon the Third Party agreement(s), or (B) grant a sublicense (with an appropriate
scope) to Intrexon under the Third Party agreement(s). Thereafter Intrexon shall be fully responsible for all obligations due for its actions under the sublicensed or assigned Third Party agreements. Notwithstanding the above, if Intrexon does not
wish to assume any financial or other obligations associated with a particular Third Party agreement identified to Intrexon under this Section 10.4(h), then Intrexon shall so notify Oragenics and Oragenics shall not make such assignment or
grant such sublicense (or cause it to be made or granted). 
 (i) Remaining Materials. At the request of Intrexon, Oragenics shall
transfer to Intrexon all quantities of Reverted Product (including final products or work-in-process) in the possession of Oragenics or its Affiliates. Oragenics shall transfer to Intrexon all such quantities of Reverted Products without charge,
except that Intrexon shall pay the reasonable costs of shipping. 
 (j) Third Party Vendors. At Intrexon’s request, Oragenics
shall promptly provide to Intrexon copies of all agreements between Oragenics or its Affiliates and Third Party suppliers, vendors, or distributors that relate to the supply, sale, or distribution of Reverted Products in the Territory. At
Intrexon’s request, Oragenics shall promptly: (A) with respect to such Third Party agreements relating solely to the applicable Reverted Products and permitting assignment, immediately assign (or cause to be assigned), such agreements to
Intrexon, and (B) with respect to all other such Third Party agreements, Oragenics shall reasonably cooperate to assist Intrexon in obtaining the benefits of such agreements. Oragenics shall be liable for any costs associated with assigning a
Third Party agreement to Intrexon or otherwise obtaining the benefits of such agreement for Intrexon, to the extent such costs are directly related to Oragenics’ breach. For the avoidance of doubt, Intrexon shall have no obligation to assume
any of Oragenics’ obligations under any Third Party agreement. 

  
 48 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (k) Commercialization. Intrexon shall have the right to develop and Commercialize the
Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Oragenics, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

 (l) Confidential Information. Each Party shall promptly return, or at the other Party’s request destroy, any Confidential
Information of the other Party in such Party’s possession or control at the time of termination; provided, however, that each Party shall be permitted to retain (i) a single copy of each item of Confidential Information of the other Party
in its confidential legal files for the sole purpose of monitoring and enforcing its compliance with Article 7, (ii) Confidential Information of the other Party that is maintained as archive copies on the recipient Party’s disaster
recovery and/or information technology backup systems, or (iii) Confidential Information of the other Party necessary to exercise such Party’s rights in Retained Products (in the case of Oragenics) or Reverted Products (in the case of
Intrexon). The recipient of Confidential Information shall continue to be bound by the terms and conditions of this Agreement with respect to any such Confidential Information retained in accordance with this Section 10.4(l). 

10.5 Surviving Obligations. Termination or expiration of this Agreement shall not affect any rights of either Party arising out of any
event or occurrence prior to termination, including, without limitation, any obligation of Oragenics to pay any amount which became due and payable under the terms and conditions of this Agreement prior to expiration or such termination. The
following portions of this Agreement shall survive termination or expiration of this Agreement: Sections 3.1 (as applicable with respect to 10.4(b), 5.5, 5.7 (only as to any pre-termination period), 6.1, 6.2 (with subsection (c) surviving only
to the extent relating to Intrexon Patents that are relevant to Retained Products that, to Intrexon’s knowledge, are being developed or Commercialized at such time, if any), 4.10, 4.11, 7.1, 7.2, 7.4, 7.5, 10.4, and 10.5; Articles 9 (excluding
9.5), 11, and 12; and any relevant definitions in Article 1. Further, Article 7 and Sections 4.5(a), 4.5(c), 5.2 through 5.9, and 9.5 will survive termination of this Agreement only to the extent there are any applicable Retained Products. 

ARTICLE 11 

DISPUTE RESOLUTION 

11.1 Disputes. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this
Agreement in an expedient manner by mutual cooperation and without resort to litigation. In the event of any disputes, controversies or differences which may arise between the Parties out of or in relation to or in connection with this Agreement
(other than disputes arising from a Committee), including, without limitation, any alleged failure to perform, or breach, of this Agreement, or any issue relating to the interpretation or application of this Agreement, then upon the request of
either Party by written notice, the Parties agree to meet and discuss in good faith a possible resolution thereof, which good faith efforts shall include at least one in-person meeting between the Executive Officers of each Party.


  
 49 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
If the matter is not resolved within thirty (30) days following the written request for discussions, either Party may then invoke the provisions of Section 11.2. For the avoidance of
doubt, any disputes, controversies or differences arising from a Committee pursuant to Article 2 shall be resolved solely in accordance with Section 2.4. 

11.2 Arbitration. Any dispute, controversy, difference or claim which may arise between the Parties and not from a Committee, out of or
in relation to or in connection with this Agreement (including, without limitation, arising out of or relating to the validity, construction, interpretation, enforceability, breach, performance, application or termination of this Agreement) that is
not resolved pursuant to Section 11.1 shall, subject to Section 11.10, be settled by binding “baseball arbitration” as follows. Either Party, following the end of the thirty (30) day period referenced in Section 11.1,
may refer such issue to arbitration by submitting a written notice of such request to the other Party. Promptly following receipt of such notice, the Parties shall meet and discuss in good faith and seek to agree on an arbitrator to resolve the
issue, which arbitrator shall be neutral and independent of both Parties and all of their respective Affiliates, shall have significant experience and expertise in licensing and partnering agreements in the pharmaceutical and biotechnology
industries, and shall have some experience in mediating or arbitrating issues relating to such agreements. If the Parties cannot agree on a single arbitrator within fifteen (15) days of request by a Party for arbitration, then each Party shall
select an arbitrator meeting the foregoing criteria and the two (2) arbitrators so selected shall select within ten (10) days of their appointment a third arbitrator meeting the foregoing criteria. Within fifteen (15) days after an
arbitrator(s) is selected (in the case of the three-person panel, when the third arbitrator is selected), each Party will deliver to both the arbitrator(s) and the other Party a detailed written proposal setting forth its proposed terms for the
resolution for the matter at issue (the “Proposed Terms” of the Party) and a memorandum (the “Support Memorandum”) in support thereof. The Parties will also provide the arbitrator(s) a copy of this Agreement, as it
may be amended at such time. Within fifteen (15) days after receipt of the other Party’s Proposed Terms and Support Memorandum, each Party may submit to the arbitrator(s) (with a copy to the other Party) a response to the other
Party’s Support Memorandum. Neither Party may have any other communications (either written or oral) with the arbitrator(s) other than for the sole purpose of engaging the arbitrator or as expressly permitted in this Section 11.2; provided
that, the arbitrator(s) may convene a hearing if the arbitrator(s) so chooses to ask questions of the Parties and hear oral argument and discussion regarding each Party’s Proposed Terms. Within sixty (60) days after the arbitrator’s
appointment, the arbitrator(s) will select one of the two Proposed Terms (without modification) provided by the Parties that he or she believes is most consistent with the intention underlying and agreed principles set forth in this Agreement. The
decision of the arbitrator(s) shall be final, binding, and unappealable. For clarity, the arbitrator(s) must select as the only method to resolve the matter at issue one of the two sets of Proposed Terms, and may not combine elements of both
Proposed Terms or award any other relief or take any other action. 
 11.3 Governing Law. This Agreement shall be governed by and
construed under the substantive laws of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction.


  
 50 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 11.4 Award. Any award to be paid by one Party to the other Party as determined by the
arbitrator(s) as set forth above under Section 11.2 shall be promptly paid in United States dollars free of any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by
law, be charged against the losing Party. Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 11, and agrees that, subject to the United States Federal Arbitration Act, 9 U.S.C. §§ 1-16,
judgment may be entered upon the final award in any United States District Court located in New York and that other courts may award full faith and credit to such judgment in order to enforce such award. The award shall include interest from the
date of any damages incurred for breach of the Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrator(s). With respect to money damages, nothing contained herein shall be construed to permit the arbitrator(s)
or any court or any other forum to award consequential, incidental, special, punitive or exemplary damages. By entering into this agreement to arbitrate, the Parties expressly waive any claim for consequential, incidental, special, punitive or
exemplary damages. The only damages recoverable under this Agreement are direct compensatory damages. 
 11.5 Costs. Each Party shall
bear its own legal fees. The arbitrator(s) shall assess his or her costs, fees and expenses against the Party losing the arbitration. 

11.6 Injunctive Relief. Nothing in this Article 11 will preclude either Party from seeking equitable relief or interim or provisional
relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of
such Party or to preserve the status quo pending the arbitration proceeding. Specifically, the Parties agree that a material breach by either Party of its obligations in Section 3.4 or Article 7 of this Agreement may cause irreparable harm to
the other Party, for which damages may not be an adequate remedy. Therefore, in addition to its rights and remedies otherwise available at law, including, without limitation, the recovery of damages for breach of this Agreement, upon an adequate
showing of material breach of such Section 3.4 or Article 7, and without further proof of irreparable harm other than this acknowledgement, such non-breaching Party shall be entitled to seek (a) immediate equitable relief, specifically
including, but not limited to, both interim and permanent restraining orders and injunctions, without bond, and (b) such other and further equitable relief as the court may deem proper under the circumstances. For the avoidance of doubt,
nothing in this Section 11.6 shall otherwise limit a breaching Party’s opportunity to cure a material breach as permitted in accordance with Section 10.2. 

11.7 Confidentiality. The arbitration proceeding shall be confidential and the arbitrator(s) shall issue appropriate protective orders
to safeguard each Party’s Confidential Information. Except as required by law, no Party shall make (or instruct the arbitrator(s) to make) any public announcement with respect to the proceedings or decision of the arbitrator(s) without prior
written consent of the other Party. The existence of any dispute submitted to 

  
 51 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
arbitration, and the award, shall be kept in confidence by the Parties and the arbitrator(s), except as required in connection with the enforcement of such award or as otherwise required by
applicable law. 
 11.8 Survivability. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after
termination of this Agreement for any reason. 
 11.9 Jurisdiction. For the purposes of this Article 11, the Parties acknowledge
their diversity and agree to accept the jurisdiction of any United States District Court located in New York for the purposes of enforcing or appealing any awards entered pursuant to this Article 11 and for enforcing the agreements reflected in this
Article 11 and agree not to commence any action, suit or proceeding related thereto except in such courts. 
 11.10 Patent Disputes.
Notwithstanding any other provisions of this Article 11, and subject to the provisions of Section 6.2, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Intrexon Patents shall be submitted
to a court of competent jurisdiction in the country in which such Patent was filed or granted. 
 ARTICLE 12 

GENERAL PROVISIONS 

12.1 Use of Name. No right, express or implied, is granted by this Agreement to either Party to use in any manner the name of the other
or any other trade name or trademark of the other in connection with the performance of this Agreement, except that (a) either Party may use the name of the other Party as required by law or regulation and in press releases accompanying
quarterly and annual earnings reports approved by the Audit Committee of the issuer’s Board of Directors, and (b) Oragenics may use the Intrexon Trademarks in accord with the licenses and restrictions set forth herein. 

12.2 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR
INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION
RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 9, OR DAMAGES AVAILABLE FOR BREACHES OF THE OBLIGATIONS SET FORTH IN ARTICLE 7. 
 12.3
Independent Parties. Neither Party is the employee or legal representative of the other Party for any purpose. Neither Party shall have the authority to enter into any contracts in the name of or on behalf of the other Party. This Agreement
shall not constitute, create, or in any way be interpreted as a joint venture, partnership, or business organization of any kind. 

  
 52 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 12.4 Notice. All notices, including notices of address change, required or permitted
to be given under this Agreement shall be in writing and deemed to have been given when delivered if personally delivered or sent by facsimile (provided that the party providing such notice promptly confirms receipt of such transmission with the
other party by telephone), on the business day after dispatch if sent by a nationally-recognized overnight courier and on the third business day following the date of mailing if sent by certified mail, postage prepaid, return receipt requested. All
such communications shall be sent to the address or facsimile number set forth below (or any updated addresses or facsimile number communicated to the other Party in writing): 

 

			
	If to Intrexon and/or Actobiotics:		 Intrexon Corporation
 20374 Seneca Meadows
Parkway
 Germantown, MD 20876
 Attention: Senior Vice
President, Health Sector
 Fax: (301) 556-9901

		
	with a copy to:		 Intrexon Corporation
 20374 Seneca Meadows
Parkway
 Germantown, MD 20876
 Attention: Legal Department

Fax: (301) 556-9902

		
	If to Oragenics:		 Oragenics, Inc.
 4902 Eisenhower Boulevard,

Suite 125,
 Tampa, FL 33634

Attention: Chief Executive Officer
 Fax: (813)
286-7904

		
	with a copy to:		 Shumaker, Loop & Kendrick, LLP
 101 E.
Kennedy Blvd., Suite 2800
 Tampa, FL 33602
 Attention: Mark
Catchur, Esq.
 Fax: (813) 229-1660


 12.5 Severability. In the event any provision of this Agreement is held to be invalid or unenforceable,
the valid or enforceable portion thereof and the remaining provisions of this Agreement will remain in full force and effect. 
 12.6
Waiver. Any waiver (express or implied) by either Party of any breach of this Agreement shall not constitute a waiver of any other or subsequent breach. 

12.7 Entire Agreement; Amendment. This Agreement, including any exhibits attached hereto, constitute the entire, final, complete and
exclusive agreement between the Parties and supersede all previous agreements or representations, written or oral, with respect to 

  
 53 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
the subject matter of this Agreement (including any prior confidentiality agreement between the Parties). All information of Intrexon or Oragenics to be kept confidential by the other Party under
any prior confidentiality agreement, as of the Effective Date, shall be maintained as Confidential Information by such other Party under the obligations set forth in Article 7 of this Agreement. This Agreement may not be modified or amended except
in a writing signed by a duly authorized representative of each Party. 
 12.8 Non-assignability; Binding on Successors. Any
attempted assignment of the rights or delegation of the obligations under this Agreement shall be void without the prior written consent of the non-assigning or non-delegating Party; provided, however, that either Party may assign its rights or
delegate its obligations under this Agreement without such consent (a) to an Affiliate of such Party or (b) to its successor in interest in connection with any merger, acquisition, consolidation, corporate reorganization, or similar
transaction, or sale of all or substantially all of its assets, provided that such assignee agrees in writing to assume and be bound by the assignor’s obligations under this Agreement. This Agreement shall be binding upon, and inure to the
benefit of, the successors, executors, heirs, representatives, administrators and permitted assigns of the Parties. Notwithstanding the foregoing, in the event that either Party assigns this Agreement to its successor in interest by way of merger,
acquisition, consolidation, corporate reorganization, or similar transaction, or sale of all or substantially all of its assets (whether this Agreement is actually assigned or is assumed by such successor in interest or its affiliate by operation of
law (e.g., in the context of a reverse triangular merger)), the intellectual property rights of such successor in interest or any of its Affiliates other than those licensed in this Agreement shall be automatically excluded from the rights licensed
to the other Party under this Agreement. 
 12.9 Force Majeure. Neither Party shall be liable to the other for its failure to perform
any of its obligations under this Agreement, except for payment obligations, during any period in which such performance is delayed because rendered impracticable or impossible due to circumstances beyond its reasonable control, including without
limitation earthquakes, governmental regulation, fire, flood, labor difficulties, civil disorder, acts of terrorism and acts of God, provided that the Party experiencing the delay promptly notifies the other Party of the delay. 

12.10 No Other Licenses. Neither Party grants to the other Party any rights or licenses in or to any intellectual property, whether by
implication, estoppel, or otherwise, except to the extent expressly provided for under this Agreement. 
 12.11 Non-Solicitation.
During the Term and for a period of one (1) year following the end of the Term, neither Oragenics nor Intrexon may directly or indirectly solicit in order to offer to employ, engage in any discussion regarding employment with, or hire any
employee of the other Party or an individual who was employed by the other party within one (1) year prior to such solicitation, discussion, or hire, without the prior approval of such other Party. General employment solicitations or
advertisements shall not be considered direct or indirect solicitations, and are not prohibited under this Agreement. 

  
 54 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 12.12 Legal Compliance. The Parties shall review in good faith and cooperate in taking
such actions to ensure compliance of this Agreement with all applicable laws. 
 12.13 Further Assurances. Intrexon shall cause
Actobiotics to take such actions and do such things as may be reasonably necessary to carry out the provisions of this Agreement applicable to Actobiotics and Intrexon shall refrain from taking any action that would reasonably be expected to cause
Actobiotics to be unable to take such actions and do such things as may be reasonably necessary to carry out the provisions of this Agreement applicable to Actobiotics. 

12.14 Counterparts. This Agreement may be executed in any number of counterparts (including by facsimile, PDF, or other means of
electronic communication), each of which taken together will constitute one and the same instrument, and any of the Parties hereto may execute this Agreement by signing any such counterpart. 

[Remainder of page intentionally left blank.] 

  
 55 









 CONFIDENTIAL TREATMENT REQUESTED BY ORAGENICS, INC. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 IN WITNESS WHEREOF, the Parties hereto
have duly executed this Exclusive Channel Collaboration Agreement. 
  

									
	INTREXON CORPORATION				ORAGENICS, INC.
					
	By:		 /s/ Gregory Frost, PhD
				BY:		 /s/ Michael Sullivan

					
	Name:		 Gregory Frost, PhD
				Name:		 Michael Sullivan

					
	Title:		 Senior Vice President, Health Sector
				Title:		 Chief Financial Officer

				
	INTREXON ACTOBIOTICS NV						
					
	By:		 /s/ Pieter Rottiers
						
					
	Name:		 Pieter Rottiers
						
					
	Title:		 Chief Executive Officer
						

 [SIGNATURE PAGE FOR EXCLUSIVE CHANNEL COLLABORATION AGREEMENT] 

  
 56